# Survival Prediction Landscape: An In-Depth Systematic Literature Review on Activities, Methods, Tools, Diseases, and Databases

Ahtisham Fazeel Abbasi<sup>1,2,\*,+</sup>, Muhammad Nabeel Asim<sup>1,+</sup>, Sheraz Ahmed<sup>1</sup>, Sebastian Vollmer<sup>1,2</sup>, and Andreas Dengel<sup>1,2</sup>

<sup>1</sup>Deutsches Forschungszentrum für Künstliche Intelligenz (DFKI), 67663, Kaiserslautern, Germany <sup>2</sup>Rhineland-Palatinate Technical University of Kaiserslautern-Landau, 67663, Kaiserslautern, Germany

### ABSTRACT

Survival prediction integrates patient-specific molecular information and clinical signatures to forecast the anticipated time of an event, such as recurrence, death, or disease progression. Survival prediction proves valuable in guiding treatment decisions, optimizing resource allocation, and interventions of precision medicine. The wide range of diseases, the existence of various variants within the same disease, and the reliance on available data necessitate disease-specific computational survival predictors. The widespread adoption of artificial intelligence (AI) methods in crafting survival predictors has undoubtedly revolutionized this field. However, the ever-increasing demand for more sophisticated and effective prediction models necessitates the continued creation of innovative advancements. To catalyze these advancements, the need of the hour is to bring existing survival predictors knowledge and insights into a centralized platform. The paper in hand thoroughly examines 22 existing review studies and provides a concise overview of their scope and limitations. Focusing on a comprehensive set of 74 most recent survival predictors across 44 diverse diseases, it delves into insights of diverse types of methods that are used in the development of disease-specific predictors. This exhaustive analysis encompasses the utilized data modalities along with a detailed analysis of subsets of clinical features, feature engineering methods, and the specific statistical, machine or deep learning approaches that have been employed. It also provides insights about survival prediction data sources, open-source predictors, and survival prediction frameworks.

### Introduction

According to World Health Organization (WHO), around ten thousand diseases have been discovered and each disease has unique symptoms, characteristics, and implications on human health<sup>1</sup>. Millions of people died from such diseases in the span of years 2000 to 2019, while cancers, cardiovascular, and infectious diseases persisted as the leading causes of mortality<sup>2,3</sup>. Extensive research on the intersection of life and technology has yielded a wide range of therapies and medications for various well-known diseases. However, the core idea behind traditional therapies and medications is based on the "one-size-fits-all"<sup>4</sup>. In this paradigm, a single drug is supposed to effectively treat a medical condition across a variety of patient cohorts i.e., children, old and young populations<sup>4,5</sup>. In-depth exploration and understanding of living organisms' inherent biological processes reveal that high variability in genetics and drug responses make one-size-fits-all medication ineffective<sup>4, 5</sup>.

The groundbreaking discoveries of the factors contributing to the limited effectiveness of generalized medications marked the inception of the era of precision medicine<sup>6,7</sup>. Precision medicine offers customization in tailored medical treatments based on an individual's unique genetic makeup, and optimization in drug selection and dosage based on the individual's lifestyle, and environmental factors<sup>8</sup>. Precision medicine's adoption and effectiveness have been significantly enhanced by the accurate, cost-effective, and large-scale analysis of molecular information obtained through next-generation sequencing<sup>9</sup>.

In the realm of precision medicine, survival prediction plays a pivotal role in tailoring medical treatments to individual needs<sup>10,11</sup>. Survival prediction categorizes patients into distinct risk groups that enhance the efficiency of resource allocation for the patients who are likely to gain the most benefit from specific treatments<sup>10,11</sup>. It also enables counseling of patients and their families by predicting the expected course of the disease and potential challenges<sup>10</sup>. In addition to medical treatments, survival prediction offers multiple advantages in research, particularly in the area of biomarker discovery and disease understanding<sup>12, 13</sup>. Survival prediction models provide useful information about the correlation between different features and clinical outcomes. This correlation information enables the identification of novel biomarkers associated with disease prognosis<sup>12</sup>. Moreover, researchers leverage survival prediction to unravel disease heterogeneity which helps to identify distinct subtypes with different survival profiles<sup>14</sup>. This knowledge not only aids in the stratification of homogeneous patients in clinical trials but also validates therapeutic targets by assessing their relevance in predicting patient outcomes<sup>15</sup>. Furthermore, it enables the longitudinal monitoring of disease progression that helps to explore critical time points and progression patterns<sup>16</sup>.



Figure 1. An end-to-end survival prediction pipeline.

To expedite advancements in survival prediction research, researchers are harnessing the capabilities of AI algorithms by utilizing extensive survival-related data from public databases such as the Cancer Genome Atlas Program (TCGA)<sup>17</sup>, and NCI Genomic Data Commons (GDC)<sup>1819–24</sup>. In addition, the diversity and heterogeneity of diseases hinder the development of a universally applicable survival prediction pipeline<sup>14,25</sup>.

Following the need for disease-specific predictors, there is a marathon for the development of more accurate and powerful predictors<sup>26–28</sup>. Figure 1 illustrates that for the advancement of survival predictors, public databases provide a spectrum of clinical data<sup>29,30</sup> and encompass 9 diverse omics data modalities, including gene expression (mRNA), micro RNA (miRNA), DNA methylation, copy number variation (CNV), long non-coding RNA (lncRNA), proteomics, metabolic, whole exome sequencing (WES) and mutation<sup>23,26,31,32</sup>. In each data modality, there exists an array of missing values that hinder survival predictors learning. Extensive research is being conducted to impute missing values by using different techniques such as deletion, multiple, K-nearest neighbor (KNN), and median imputation<sup>33–35</sup>. In addition, various normalization methods are also being used to normalize feature space such as quantile, variance threshold, and rank normalizations<sup>36</sup>.

In the development of survival prediction pipelines, researchers are trying to unlock the potential of various data modalities by assessing predictor performance with individual modalities and combinations of multiple data modalities across diverse types of diseases. When data from different modalities is combined, survival predictors' input feature space becomes very large which impedes the performance of AI approaches<sup>37</sup>. Researchers are trying to explore feature engineering approaches such as random forest importance (RFI), and recursive feature elimination (RFI)<sup>38</sup>, principal component analysis (PCA)<sup>31,39</sup>, non-negative matrix factorization (NMF)<sup>40</sup>, and autoencoders (AEs)<sup>41-43</sup>. Moreover, in an end-to-end survival predictive pipeline, apart from the selection of appropriate data and feature engineering strategy, designing appropriate survival prediction models is also an active area of research.

Under different aforementioned directions, the recent 3 years have witnessed around 74 different survival predictors for different diseases. To further accelerate and expedite the development of more powerful predictors, in the last 10 years, from time to time, researchers have published 22 different review articles. These articles primarily aim to summarize the latest trends and developments in data modalities, feature engineering methods, and AI models specifically related to survival prediction. However, the focus of these reviews is often constrained to either a singular disease or multiple subtypes of cancer, highlighting a limited scope within the broader landscape of survival prediction research<sup>37,44–48</sup>. More comprehensive details about the scope of existing review articles in terms of contributions and drawbacks are summarised in Table 1 and section . Following the need for a comprehensive

review article for survival prediction, the contributions of this paper are manifold:

- It consolidates a diverse array of 22 survival prediction review papers, bringing together their scopes and limitations under a unified umbrella. This compilation serves as a valuable resource for researchers seeking high-level insights and pertinent information in the field.
- It provides comprehensive insights into 74 survival prediction articles published between 2020 and 2023.

The objective is to delve into diverse aspects of the field, extract and furnish useful information from these articles under the following different research questions and objectives: i) What is the distribution of 74 research articles across 44 different diseases, and how does it vary among cancer subtypes and other diseases? ii) How do studies address the spectrum of survival prediction, from a broader perspective covering multiple cancer subtypes to individual subtypes? iii) What are the predominant survival endpoints used in studies, and how are studies distributed across four endpoints overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and biochemical recurrence (BC)? iv) What are the most commonly used public and private data sources in existing survival prediction studies and the types of data they encompass? v) What are the most commonly used omics data modalities and their associations with different diseases and survival endpoints? vi) Which clinical features are most commonly employed in survival prediction studies? vii) How have feature engineering techniques evolved across different data modalities, diseases, and survival endpoints in survival prediction studies? viii) Which specific statistical, machine learning (ML), and deep learning (DL) survival prediction algorithms have been applied to diverse diseases and survival endpoints? ix) Which survival prediction studies have made their source codes publicly available, and what types of methods are available in open-source survival prediction frameworks? x) What are the most commonly utilized survival prediction evaluation measures? xi) Which conferences and journals predominantly publish survival prediction studies?

### Background

Survival prediction makes use of patient-specific molecular information and clinical signatures to forecast a wide range of events at particular time intervals. The most common events include recurrence, metastasis, response, recovery, hospitalization, and progression of a disease. Some of these events represent similar contexts, i.e., metastasis and progression both contribute to the overall progression of the condition/cancer. Survival prediction events are generally categorized into 4 different survival endpoints namely, overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and biochemical recurrence (BC). Survival endpoints serve as crucial measures for assessing the outcomes of interventions, indicating the duration until specific events occur. Therefore,

events are essentially the occurrences that contribute to the survival endpoints. These endpoints are critical to examine the trajectory of a particular disease.

Survival prediction is time to event approach with two distinct aspects, i.e., survival and hazard function. Survival function describes the probability that a subject survives longer than some specified time t. Mathematically, it is expressed as:

$$S(t) = P(T > t), \tag{1}$$

where T is the random variable for survival time, t is a specific value of interest for T. For instance, S(10) represents the probability of survival beyond 10 years without experiencing a specific event. As time passes, S(t) decreases, reflecting the reduction in the probability of surviving without the occurrence of event E up to time t.

In comparison, the hazard function illustrates the probability of an event E occurring at a specific time interval ( $\Delta t$ ) with a prior assumption that the event has not taken place. The probability that the event *E* occurs within a very small time interval  $\Delta t$  around time t is given by the conditional probability:

$$P(t \le T < t + \Delta t \mid T \ge t) \tag{2}$$

Dividing this probability by the length of the time interval  $(\Delta t)$  gives the rate of occurrence of the event at time t. The limit as the time interval ( $\Delta t$ ) approaches zero gives the instantaneous rate of occurrence at time t. Mathematically, this is represented as:

$$h(t) = \lim_{(\Delta t \to 0)} \frac{Pr(t \le T < t + \Delta t \mid T \ge t)}{\Delta t} = \frac{f(t)}{S(t)} \quad (3)$$

P(individual fails in the interval  $[t, t + \Delta t]$  | survival up to time t) do not explore the potential of multionics data in terms of (4)

where f(t) represents the probability density function of survival time. Thus, survival function S(t) shows that the subject survives beyond a specific time point and hazard function h(t) complements this by providing a risk rate that a patient does not survive in a specific time interval conditioned on having survived thus far. Moreover, S(t) is always monotonic in nature, however h(t) is classically assumed to follow increasing Weibull, decreasing Weibull, or lognormal survival curves.

### A Look-back Into Existing Review Studies

In recent years multiple review papers have been published and the objective of each review revolves around summarising fundamental concepts in survival prediction and identifying trends in statistical, ML, and DL algorithms that have been utilized in the development of survival predictors. Table 1

illustrates a high-level overview of the existing 22 review articles in terms of their review scope and limitations. This comprehensive summary aims to assist researchers in locating specific information within relevant articles more effectively.

In Table 1, a comprehensive analysis of the scope of review articles indicates that existing studies can be classified into three distinct groups. I) 9 review papers primarily focus on the application of DL algorithms in survival prediction<sup>47,49–56</sup> , II) 7 review papers summarise the application of ML algorithms in survival prediction<sup>37,48,57–61</sup>, and 6 review papers summarise survival prediction methods from three different categories namely statistical, ML, and DL methods<sup>44–46,62–64</sup>.

On the other hand, in the realm of disease specific survival predictors scope of existing review papers is limited. For instance, 8 papers only summarize survival predictors on single disease or subtype of cancer, i.e., cervical cancer<sup>46</sup>, glioblastoma<sup>63</sup>, esophageal adenocarcinoma<sup>48</sup>, esophageal and gastroesophageal junction cancer<sup>57</sup>, head and squamous cell carcinoma<sup>61</sup>, palliative cancer patients<sup>47</sup>, cardiovascular diseases (CVD)<sup>64,65</sup>, and schizophrenia<sup>60</sup>. Although 4 papers cover multiple subtypes of cancer but they cover only handful of 8 different subtypes such as, breast, lung, gastric, colon, esophageal, ovarian cancers and so on.

While the scope of survival prediction extends beyond multiple diseases, existing review papers fall short to summarize current trends of data modalities, feature engineering approaches and survival prediction models. For example, Deepa et al.<sup>44</sup> specifically address the primary categories of data modalities used for survival prediction, namely multiomics and clinical data. However, the review does not extensively explore trends and patterns related to the 9 different omics types i.e., gene expression (mRNA), micro RNA (miRNA), methylation, copy number variation (CNV), whole exome sequencing (WES), long noncoding RNA (lncRNA), mutation, metabolic, and proteomics, or clinical features associated  $Pr(t \le T < t + \Delta t \mid T \ge t) =$  with distinct cancer subtypes. Similarly, Westerlund et al.<sup>64</sup> cardiovascular diseases. In addition, various review papers completely neglect to address feature engineering in survival prediction<sup>46,47,52,56,57,62</sup>. For instance, Feldner et al.<sup>37</sup> despite their focus on dimensionality reduction, fall short in providing a comprehensive summary of current trends in feature engineering approaches with respect to diseases and data modalities. Futhermore, a small portion of these review papers cover details of few state of the art survival prediction models<sup>49,52,56</sup>. While current review papers summarize survival prediction pipelines partially, there is a necessity to bring diverse information into a unified platform which offers comprehensive insights into patterns and trends associated with survival prediction pipelines.

Article	Citation	s Number of Articles	Scope	Shortcomings
Deepa et al., <sup>44</sup>	17	37	Cancer survival, subtypes, and recurrence predic- tion across 7 cancer subtypes i.e., breast, lung, gastric, cervical, oral, cystic fibrosis, and multi- cancers	Does not take into account all types of cancers, and other diseases on the basis of multiomics and clinical data
Hermann et al., <sup>45</sup>	59	NS	A benchmark of different ML and statistical sur- vival analysis methods on multiple cancer datasets from TCGA i.e., bladder, breast invasive, colon, esophegeal, head-neck squamous, kidney renal, cervical kidney, acute myloid leukemia, low grade glioma, liver hepatocellular, lung adenocarcinoma, lung squamous, ovarian cancer, oancreatic, sar- coma, skin cutaneous, stomach, and Uterine corpus cancers.	A benchmark with a limited number of methods for survival modeling.
Rahimi et al., <sup>46</sup>	2	13	Cervical cancer (CC) survival analysis based on ML and statistical methods to predict Disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS)	The review is confined to cervical cancer survival prediction and does not encompass deep learning-based methods.
Bashiri et al., <sup>62</sup>	80	17	Survival Prediction based on gene expression data across Mantle cell lymphoma, esophageal adeno- carcinoma, Esophageal squamous cell carcinoma, Non- small cell lung carcinomas, Diffuse large B- Cell lymphoma (DLBCL), astrocytic tumor, and Lung cancer	Multiomics data is not extensively discussed, as it is understood that the emphasis on gene expression alone may not define the survival of a sub- ject.
Tewarie et al., <sup>63</sup>	23	27	Continous and discrete-time survival prediction across glioblastoma based on magnetic resonance images (MRI), genomics, and clinical data	The review paper does not include a discussion of survival prediction models. Also, the role of multiomics data in survival prediction has not been explored.
Westerlund et al., <sup>64</sup>	d 23	NS	Risk prediction in cardiovascular diseases (CVD) based on clinical, and image data, and molecular signatures such as single nucleotide polymorphism (SNP).	-
Kresoja et al., <sup>65</sup>	5	NS	An overall spectrum of survival prediction in car- diovascular diseases is presented based on the im- age, omics, and clinical data.	-
Wiegrebe et al., <sup>49</sup>	4	58	Survival prediction with DL models from 5 ma- jor categories i.e., discrete-time, piece- wise expo- nential, parametric, ranking-based, and ordinary differential equation (ODE)	While it encompasses numerous models, the paper still lacks coverage of information related to ML models.
Salerno et al., <sup>50</sup>	5	NS	ML and DL based methods are discussed for sur- vival analysis with a focus on high dimensional- ity of the data. Mainly, regularized cox models, support vector machines, random survival forests, boosting, and artificial neural networks are pre- sented.	Only a handful of methods are discussed in this specific review whereas, the number of methods used to deal with high dimensional data is significant in number.
Pobar et al., <sup>47</sup>	15	16	DL for survival prediction in palliative cancer pa- tients (advanced cancer patients) on the basis of radiomics data and evaluation based on Palliative Prognostic Score (PaP), Palliative Prognostic Index (PPI) and Number of Risk Factors (NRF)	The prime focus is only related to radiomics-based methods.

**Table 1.** The scope and limitations of current survey papers.

Bakasa et al., <sup>51</sup>	16	NS	Pancreatic survival prediction models and the use of DL models such as image segmentation, and feature extraction. Different concepts like image segmentation and feature extraction are discussed in detail with less emphasis on their utilization in ML or DL-based survival prediction. In addition, very few studies are referred related to pancreatic cancer survival prediction	
Ahmed et al., <sup>52</sup>	252	NS	The internal components of artificial neural net- works (ANNs)	Authors provide a rough overview of artificial neural networks (ANNs). At the time of this publication, there was approximately very little at- tention given to survival predic- tion using ML and DL-based mod- els. Therefore, the review discusses only the internal workings of ANNs rather than discussing the details of survival prediction and the role of AI in it.
Kantidakis et al., <sup>56</sup>	3	24	Studies related to survival prediction are presented in two different settings i.e., setting 1: time is added as part of the input features and a single output node is specified, setting 2: multiple output nodes are defined for each time interval	Authors discuss different types of neural network setting used for sur- vival analysis yet they did not cate- gorize all the studies related to sur- vival analysis on the basis of the type of neural network setting being used.
Altuhaifa et al., <sup>53</sup>	0	30	Studies related to cancer survival prediction. The authors present databases utilized for the prediction of cancer survival prediction along with feature selection algorithms, types and nature of features, survival prediction models, and limitations.	Lack of characterization with re- spect to the multiomics-based data modalities.
Wekesa et al., <sup>54</sup>	0	NS	radiomics, and multiomics studies related to dif- ferent factors that play a critical role in various diseases i.e., miRNA, circRNA, and so on are pre- sented. The prime focus is on data integration techniques based on DL for interaction prediction, disease diagnosis, and treatment.	Only a handful of studies are cov- ered
Kvamme et al., <sup>55</sup>	47	NS	Authors discuss in detail the architectures and schemes utilized to predict survival in a discrete or continuous fashion.	-
Feldner <sup>37</sup>	13	NS	Dimensionality reduction in ML models with con- text to cancer subtype identification, and survival prediction.	The prime focus is on the use of dimensionality reduction in multi- omics related tasks. The role of di- mensionality reduction in survival prediction has not been covered in this review.
Boshier et al., <sup>48</sup>	0	17	Survival prediction in esophageal adenocarcinoma is discussed on the basis of clinical data. In addi- tion, various survival prediction models are eval- uated on new validation data comprised of 2450 patients.	Only limited to a single cancer and the focus is only related to clinical data.

Gupta et al., <sup>57</sup>	38	16	Prognostication in terms of esophageal and gastroe- sophageal junction cancer on the basis of image and clinical data.	Lack of multiomics-based analysis.
Wissel et al., <sup>58</sup>	-	-	Authors discuss and propose new standardized benchmark datasets and their splits for survival prediction, obtained from TCGA, TARGET, and ICGC databases. The comparison of the AI-based and statistical models is also presented in the pa- per which shows that statistical models often beat AI-based models in time to event prediction with multiomics data.	-
Lee et al., <sup>59</sup>	62	NS	Different concepts related to survival analysis are discussed i.e., survival functions, Kalpan Meier estimators, and log-rank test. In addition, multiple time-to-event modeling approaches are also pre- sented in detail such as, Cox-PH model, random survival forest, survival support vector machines, bagging, cox boosting, and artificial neural net- works.	Limited coverage of omics-based modalities and an in-depth discus- sion.
Guan et al., <sup>60</sup>	40	NS	Subtyping and risk prediction in Schizophrenia.	-
Mo et al., <sup>61</sup>	0	NS	A comparison of 12 supervised ML models to predict the outcome of head and squamous cell carcinoma i.e., bayesian network, naive Bayes, logistic regression, generalized linear model, k- nearest neighbor, decision tree, random forest, bootstrap aggregating, and AdaBoost, gradient boosting trees, neural network, and support vector machine. In addition, important genes are further validated using a variety of wet lab experiments.	Only a single multiomics data is used for the comparison of different survival outcome prediction models, whereas multiple datasets can show the generalizability of the models on the data belonging to various demo- graphic locations.
Ours	-	74	A systematic analysis of diverse survival predic- tion literature. This review encompasses ML, DL, and statistical survival predictors across more than 30 different diseases. In addition, the review ad- dresses diverse research questions related to the distribution of survival predictors, databases, data modalities, feature engineering methods, survival prediction models, source codes and libraries for the development of survival predictors, and various evaluation measures.	This review paper focuses solely on current trends in survival predic- tion, omitting basic terminologies and mathematical formulations. For a concise mathematical overview, readers are advised to consult ear- lier review papers <sup>55, 59</sup> .

### Results

# **RQ I, II, III:** Survival predictors distribution analysis across diseases and survival endpoints

The primary aim of this section is to summarise the distribution of survival predictors across various diseases and survival endpoints. Predictors distribution analysis under individual diseases offers insights into the most active trends of predictors associated with specific diseases. This consolidated distribution provides a centralized platform to access valuable information about their disease of interest. Similarly, examining the distribution of articles across survival endpoints is valuable for identifying current trends in forecasting multiple events. This approach not only enhances our understanding of the current state of predictive modeling but also facilitates researchers in efficiently accessing information specific to their desired endpoints. Through this exploration, we aim to contribute to a deeper understanding of the diverse landscape of survival prediction research and its applications across various diseases and endpoints.

Table 2 illustrates disease specific predictors distribution for both cancer and other diseases respectively. In the last 3 years, 60 predictors have been designed for different cancer subtypes related survival prediction<sup>24, 104, 108</sup> while only 14 predictors have been designed for other diseases such as cardiovascular diseases, COVID-19, and trauma<sup>29,112,119,120</sup>.

To date, approximately more than 100 different cancer subtypes have been identified<sup>121</sup>. However, a deeper analysis of the last 3 years reveals that survival prediction models have been developed for only 36 distinct cancer subtypes, as outlined in Table 2. Among 36 different subtypes, most of the predictors have been designed for breast cancer, lung adenocarcinoma, ovarian cancer, and glioblastoma. On the other hand, 7 different predictors have been designed for pancancer. Notably, there is a difference between other cancer types and pancancer because under this paradigm predictors simultaneously deal with multiple cancer subtypes. For the development of pancancer based predictors, there exists public data having more than 30 distinct cancer subtypes. However, researchers are utilizing different subsets for the development of predictors. Figure 3 provides an overview of multiple survival prediction studies that encompass a range of cancer subtypes, either within a pancancer context or within the context of predicting survival for different subtypes. A total of 14 studies have taken into account multiple cancer subtypes whereas the majority of the studies have only covered only a single type of cancer subtype such as colorectal cancer<sup>109</sup>, lymphoma<sup>85</sup>, colon adenocarcinoma<sup>39</sup>, gastric cancer<sup>42</sup> and so on.

Figures 2 and 4 illustrate predictors distribution across survival endpoints. A majority of studies 54 (79%) have OS as an endpoint of survival prediction<sup>28,82,101,120</sup>, whereas 7 studies have incorporated multiple survival endpoints in their analysis. Out of 7 studies, 3 studies have incorporated DFS and BC<sup>22,26,122</sup>. Two studies have incorporated OS, DFS, and PFS<sup>40,108</sup> and 2 studies have OS, and PFS as the survival end-

**Table 2.** Distribution of survival predictors across individual diseases.

Disease Subtype	Number of Studies	References
Nasopharyngeal Carcinoma:	1	66
HER2-negative metastatic breast cancer	1	67
Tripple negative breast cancer	1	68
Breast invasive carcinoma	1	14
Colon adenocarcinoma	1	39
Gastric cancer	1	42
Gastrointestinal cancer	1	30
Adult diffuse glioma	1	69
Invasive ductal carcinoma	1	70
Pancreatic cancer undergoing biliary drainage	1	71
Kidney renal clear cell carcinoma	2	14,72
Lung squamous cell carcinoma	1	14
Cervical Cancer	1	73
Neuroblastoma	1	38
Rectal cancer	1	74
Colon cancer	3	75–77
Liver Cancer	1	41
Esophageal Carcinoma	2	78,79
Stomach adenocarcinoma	1	72
Ovarian serous cystadenocarcinoma	2	72,78
Kidney renal clear cell carcinoma	2	31,72
Lower grade glioma	1	80
Head-and-neck squamous cell carcinoma	1	72
Bladder Cancer	3	40,81,82
Bladder urothelial carcinoma	1	72
Renal cell carcinoma		83,84
Lymphoma	1	85
Hepatocellular carcinoma	3	43, 86, 87
Ovarian cancer	4	86,88–90
Glioblastoma	4	90–93
Prostate Cancer	2	22,94
Non-small cell lung cancer	3	95–97
Pancreatic cancer	3	26,32
Breast Cancer	6	23,74,90,98–100
Lung adenocarcinoma	4	27,101–103
Pancancer	7	24, 28, 104–108
Colorectal Cancer	1	109
Atherosclerosis	3	29,110,111
Myocardial infarction	1	112
Stroke	1	112
COVID-19	1	113
Cardiovascular disease	6	112,114–118
Liver transplant	1	119
Trauma	1	120



Figure 2. Survival endpoint distribution across diverse studies.





**Figure 4.** Distribution of explored survival prediction streams from existing literature. DFS: disease-free survival, PFS: progression-free survival, OS: overall survival, and BC: biochemical recurrence.

**Figure 3.** Cancer subtypes coverage based on pancancer or individual subtype settings.

points<sup>31,81</sup>. A single study has focused on DFS only<sup>95</sup>, and 2 only on BC<sup>94,117</sup>. The rest of studies either did not explicitly specify their endpoints for survival prediction or predominantly concentrated on predicting patients' survival outcomes without a specific focus on distinct survival endpoints.

### RQ IV: Survival prediction data availability in public and private sources and opportunities for development of predictors

Survival prediction models development relies on the quality and quantity of annotated data, which is generated through extensive wet lab experiments. Experimental findings are stored in different types of databases that open new doors for the development of survival prediction applications. However, there exist multiple databases and each database encompasses particular diseases and modality specific survival data. For instance, CGGA<sup>124</sup> focuses on brain tumors, and MESA<sup>128</sup> contains data related to atherosclerosis. To accelerate the development of more competent survival predictors, it is essential to summarise which database contains which type of disease and what data modalities. In the highlight of research question IV, Table 3 illustrates public databases details in terms of diseases and data modalities they offer.

A deeper analysis of existing survival predictors reveals that among the 74 studies 54 utilized publicly accessible data from three key databases: the Cancer Genome Atlas Program (TCGA)<sup>17</sup>, NCI Genomic Data Commons (GDC)<sup>18</sup>, and the Gene Expression Om-nibus (GEO)<sup>31,32,72,73,80,82,87,90,91,130,131</sup>. Apart from pubdatabases, there also exist private databases that lic have been utilized in existing survival prediction studies<sup>66,75,81,112,113,117,118</sup>. However, these private databases often restrict data access and may require extensive research proposals for data retrieval. Among these databases commonly used databases are Heidelberg University Hospital<sup>30</sup>, COMBO-01<sup>71</sup>, Life cohort<sup>115</sup>, and UNOS<sup>119</sup>. The reliance on private databases for survival prediction creates significant hurdles for research in several ways. Firstly, limited accessibility to such data impedes the reproducibility and verification of study findings by other researchers, hindering the validation and robustness of predictive models. Secondly, the lack of transparency and standardized access procedures for private datasets introduces challenges in benchmarking and comparing different survival prediction models. Lastly, the exclusivity of private databases may contribute to a potential bias in research outcomes, as the diversity and representativeness of the data are often compromised which impacts the generalizability of survival predictions to broader patient cohorts.

Public access to databases enables researchers to create survival benchmark datasets that fosters the development of survival prediction models. However, many researchers develop datasets without making them public which hinders transparency and the broader scientific community progress. The lack of shared data and presence of multiple datasets associated with a single disease pose a notable challenge in survival prediction. For instance, it hinders the establishment of standardized testing and benchmarking procedures for newly proposed survival prediction methods, leading to ambiguities in identifying the most advanced techniques. Moreover, recognizing the need for standardization in benchmarking survival prediction models, Wissel et al.<sup>58</sup> introduced benchmark survival datasets tailored for both individual cancer subtypes and pancancer settings. These datasets are accessible at https://survboard.vercel.app/, contributing to a more uniform and transparent benchmarking framework within the survival prediction landscape. Particularly, here we emphasize the use of these datasets for benchmarking in addition to newly created datasets to have unified benchmarking for cancer-specific survival prediction models.

### RQ V, VI: Survival prediction data modalities and utilization of their combinations for disease and survival endpoints specific predictors development

Following the objective of research question V, the primary focus of this section is to investigate and provide a comprehensive summary of the various data modalities utilized in the development of diverse survival predictors. To address research question V, it describes the distribution of data modalities across predictors associated with four distinct survival endpoints, and 44 different diseases. Furthermore, in response to research question VI, it furnishes information regarding the specific clinical features utilized by various survival prediction studies.

Out of 74 different studies, data modalities details of only 68 studies are available. Within this subset, 14 studies exclusively used clinical data, 39 studies utilized multiomics data, and 15 studies investigated the combined potential of both clinical and multiomics data modalities. Moreover, based on characteristics of molecular information omics data is generally categorized into 9 different classes namely gene expression (mRNA), micro RNA (miRNA), methylation, copy number variation (CNV), whole exome sequencing (WES), long noncoding RNA (lncRNA), mutation, metabolic, and proteomics. The specifics of different predictors, in terms of variations in the combinations of clinical and various omics data modalities, are outlined in Table 4. Among 54 survival prediction studies based on multiomics, 49 studies utilized different combinations of four distinct omics types: mRNA, methylation, miRNA, and CNV<sup>14,26,27,42,43,69,72,73,77,82,84,89,96,97,100,101,106,108</sup>. Only 7 studies utilized additional modalities such as whole exome sequencing (WES)<sup>26,31</sup>, long coding RNA (lncRNA)<sup>31</sup>, proteomics<sup>22, 23, 108, 113, 115</sup>, and mutation data<sup>22, 23, 108, 115</sup>.

The choice of omics type hinges on the specific disease under investigation, as indicated by the disease-wise distribution of omics types in Figure 5. Out of 9 omics types, mRNA, CNV, miRNA, and methylation have been the most commonly utilized modalities for 33 cancer subtypes i.e., breast cancer<sup>14,23,68,74,90,98–100</sup>, pancancer<sup>24,91,105–108,131</sup>, colon can-

Data Source	Diseases Covered	Types of Data	URL	Description
GDAC Broad Firehose <sup>123</sup>	38 different cancer subtypes	Clinical, CNV, methylation, miRNA, mRNA, mutation, pro- teomics	<pre>https://gdac. broadinstitute. org/</pre>	The Firehose platform provides processed and analyzed data from TCGA, making it accessible to researchers for further analysis and interpretation.
Chinese Glioma Genome Atlas (CGGA) <sup>124</sup>	Brain Tumor	Clinical, single cell RNA, mRNA, image, and microarray	http://www.cgga. org.cn/	The Chinese Glioma Genome Atlas (CGGA) is a genomic database focused on glioma, providing comprehensive molecu- lar characterization and clinical information to advance the understanding and treatment of glioma tumors.
TARGET	Pediatric cancers such as osteosarcoma, neuroblastoma, rhabdoid cancer, Wilms, acute myloid leukemia, acute lymphoblastic leukemia	Clinical, mRNA, miRNA, methyla- tion, proteomic and CNV	https://www.cancer. gov/ccg/research/ genome-sequencing/ target	The TARGET (Therapeutically Applicable Research to Generate Effective Treatments) NCI (National Cancer Institute) database is dedicated to pediatric cancers, offering molecular and clinical data to facilitate re- search and the development of targeted ther- apies for pediatric cancer patients.
SEQC <sup>125</sup>	Neuroblastoma	Microarray, and mRNA	-	RNA-seq and microarray data to predict clinical/survival endpoints for neuroblas- toma,
MsigDb <sup>126</sup>	-	Curated gene sets, motif gene sets, gene ontology terms, oncogenic sig- natures, and immunologic signa- tures	https://www. gsea-msigdb.org/ gsea/msigdb	The Molecular Signatures Database (MSigDB) is a collection of annotated gene sets, pivotal for gene set enrichment analysis, encompassing diverse biological pathways and functions, aiding researchers in studying gene expression patterns.
GTEX <sup>127</sup>	54 non-diseased tissue sites across nearly 1000 individuals	Single cell, mRNA, methylation, chip-seq, histology images	https://www. gtexportal.org/ home/	The Genotype-Tissue Expression (GTEx) project is a comprehensive research initia- tive that characterizes the genetic and tissue- specific gene expression patterns across a diverse set of human tissues, providing valu- able insights into the relationship between genetic variation and gene regulation.
Kaggle	Not disease-specific	Clinical	<pre>https://www.kaggle. com/</pre>	Kaggle is an online platform that hosts data science competitions and facilitates collaboration among data scientists, offer- ing datasets and a community for learning and problem-solving. In addition, Kaggle is not specifically designed for omics-based datasets or studies.
MESA <sup>128</sup>	Heart diseases	Clinical, genetic, and imaging	https://www. mesa-nhlbi.org/ default.aspx	The Multi-Ethnic Study of Atherosclerosis (MESA) MESA is a research study by the National Heart, Lung, and Blood Institute, involves 6,000+ individuals from six U.S. communities, assessed at affiliated univer- sity clinics
UCSC Xena <sup>129</sup>	Various cancer subtypes that are present in TCGA	Clinical and omics data modalities associated with TCGA	https://xena.ucsc. edu/	UCSC Xena is a bioinformatics platform offering a user-friendly interface for the exploration and visualization of integrated multi-omic and clinical datasets, enabling researchers to analyze and interpret diverse biological and disease-related information collaboratively.
GEO <sup>130</sup>	Plethora of diseases such as cardiovascular and neurological diseases and cancers	Clinical, mRNA, miRNA, CNV, methylation, chromatin interac- tion, DNA modification, splicing, lncRNA, and mutation	https://www.ncbi. nlm.nih.gov/geo/	The Gene Expression Omnibus (GEO) is a publicly accessible repository, maintained by the National Center for Biotechnology Information (NCBI), housing a diverse col- lection of high-throughput functional ge- nomics datasets, enabling researchers to freely access and analyze gene expression and other omics data across a broad spec- trum of biological conditions and diseases. GEO does not have a specific or dedicated portal for survival prediction datasets.
TCGA/GDC <sup>17</sup>	More than 40 cancer subtypes such as glioblastoma, pancreatic, bladder, breast and rectal cancers	Clinical, mRNA, miRNA, CNV, methylation, methylation, miRNA, splicing, lncRNA, and mutation	https://www.cancer. gov/ccg/research/ genome-sequencing/ tcga	Cancer genome atlas (TCGA) generates ge- nomics data, while GDC is the platform that hosts and shares not only TCGA data but also other cancer genomics datasets, pro- moting data accessibility and collaboration in the cancer research community.

#### **Table 3.** The ample collection of survival data within diverse public databases.



Figure 5. Distribution of omics data modalities across a diverse set of diseases.

Data Madality																	Stu	dies																
Data Modality	22	30	29	81	85	118	67	71	68	14	75	86	103	95	28	98	101	24	109	96	105	113	38	74	66	94	97	99	106	107	42	92	39	27
Clinical	✓	√	$\checkmark$	√	$\checkmark$	√	$\checkmark$	√	×	×	√	×	$\checkmark$	√	×	√	$\checkmark$	√	×	$\checkmark$	×	×	×	×	√	√	×	×	×	×	×	√	×	×
mRNA	$\checkmark$	×	×	×	×	×	×	×	×	$\checkmark$	×	$\checkmark$	$\checkmark$	×	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	×	$\checkmark$	×	$\checkmark$	$\checkmark$											
miRNA	×	×	×	×	×	×	×	×	$\checkmark$	$\checkmark$	×	×	×	×	×	×	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	×	×	×	×	×	$\checkmark$	$\checkmark$	×	$\checkmark$	$\checkmark$	×	×	$\checkmark$	$\checkmark$
Methylation	$\checkmark$	×	×	×	×	×	×	×	×	$\checkmark$	×	×	×	×	$\checkmark$	×	$\checkmark$	×	×	$\checkmark$	×	×	$\checkmark$	$\checkmark$	×	$\checkmark$	$\checkmark$	×	$\checkmark$	×	$\checkmark$	×	$\checkmark$	$\checkmark$
CNV	×	×	×	×	×	×	×	×	×	×	$\checkmark$	×	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	×	×	×	×	×	×	×	×	×	$\checkmark$	×	$\checkmark$	×	×	×	$\checkmark$
Proteomics	$\checkmark$	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	$\checkmark$	×	×	×	×	×	×	×	×	×	×	×	×
Mutation	×	×	×	×	×	×	×	×	×	×	×	×	$\checkmark$	$\checkmark$	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	$\checkmark$	×	×	×	×
Metabolic	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	$\checkmark$	×	×	×	×	×	×	×	×	×	×	×	×
IncRNA	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
WES	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Data Modelity																	Stu	dies																
Data Mouanty	70	112	78	80	31	87	90	111	88	91	32	114	115	73	131	119	72	82	40	117	23	43	89	84	93	79	69	41	76	26	100	77	108	102
Clinical	$\checkmark$	$\checkmark$	$\checkmark$	×	×	×	×	$\checkmark$	×	$\checkmark$	×	$\checkmark$	$\checkmark$	×	×	$\checkmark$	$\checkmark$	×	×	×	×	×	×	×	×	×	×	×	×	$\checkmark$	×	$\checkmark$	×	×
mRNA	×	×	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	×	$\checkmark$	$\checkmark$	$\checkmark$	×	×	$\checkmark$	$\checkmark$	×	$\checkmark$																	
miRNA	×	×	×	×	$\checkmark$	×	×	×	×	×	×	×	×	$\checkmark$	$\checkmark$	×	$\checkmark$	$\checkmark$	×	×	×	$\checkmark$	$\checkmark$	$\checkmark$	×	×	×	$\checkmark$						
Methylation	×	×	$\checkmark$	$\checkmark$	$\checkmark$	×	×	×	×	$\checkmark$	$\checkmark$	×	×	$\checkmark$	$\checkmark$	×	$\checkmark$	$\checkmark$	×	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	×	$\checkmark$	×	$\checkmark$						
CNV	×	×	×	×	×	$\checkmark$	$\checkmark$	×	×	$\checkmark$	$\checkmark$	×	×	$\checkmark$	×	×	$\checkmark$	$\checkmark$	×	×	$\checkmark$	×	$\checkmark$	$\checkmark$	$\checkmark$	×	×	×	×	×	$\checkmark$	×	×	$\checkmark$
Proteomics	×	×	×	×	×	×	×	×	×	×	×	×	$\checkmark$	×	×	×	×	×	×	×	$\checkmark$	×	×	×	×	×	×	×	×	×	×	×	$\checkmark$	×
Mutation	×	×	×	×	×	×	×	×	×	×	$\checkmark$	×	×	$\checkmark$	×	×	×	×	×	×	$\checkmark$	×	×	×	×	×	$\checkmark$	×	×	×	×	×	×	×
Metabolic	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
IncRNA	×	×	×	×	$\checkmark$	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
WES	×	×	×	×	$\checkmark$	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	$\checkmark$	×	×	×	×

**Table 4.** Distribution of data modalities across diverse surival prediction studies.



Figure 6. Distribution of different omics modalities with respect to survival endpoints.

cer<sup>39,74–77</sup>, lung adenocarcinoma<sup>27,101,102</sup>, and ovarian cancer<sup>72,84,88–90,103</sup>. In addition, mutation data has been utilized for 7 cancer subtypes namely, adult diffuse glioma<sup>69</sup>, breast cancer<sup>23</sup>, cervical cancer<sup>73</sup>, non-small cell lung cancer<sup>95</sup>, ovarian cancer<sup>103</sup>, and pancreatic cancer<sup>32</sup>. Among 10 data modalities, 3 modalities namely, proteomic, lncRNA and WES have been utilized the least having limited applicability to clear renal cell cancer<sup>31</sup>, pancreatic cancer<sup>26</sup>, breast cancer<sup>23</sup>, localized prostate cancer<sup>22</sup>, and pancancer<sup>107</sup>. In terms of other diseases i.e., COVID-19 and heart diseases, proteomics, methylation, mRNA, metabolic, and methylation have been the only omics types utilized for survival prediction<sup>113,115,117</sup>.

The variability in omics-type selection is not solely bound to diseases but notably varies across a wide spectrum of survival endpoints. Figure 6 shows the counts of different omics types that have been utilized for different survival endpoints prediction. In the context of OS prediction, mRNA, miRNA, methylation, and CNV have been primarily utilized in more than 30 studies, with 10 studies based on proteomics, mutation, and metabolic data. However, in terms of DFS and PFS the selection of omics types appears less distinct. These endpoints have been frequently studied in conjunction with OS, predominantly utilizing mRNA, miRNA, and methylation data. This combination suggests a commonality in the predictive factors across these survival endpoints, indicating potential interconnections or shared biological processes.

Clinical data modality has been utilized in 29 different studies. However, in this modality number of features varied from study to study and it is still unclear which particular set of features is most important. To perform an in-depth analysis, which study utilized which subset of features across diverse cancer subtypes and heart diseases, a comprehensive collection of clinical features is presented in Table 5. In order to better understand and discern the trends in clinical features across diverse diseases, hereby they are placed in 7 different categories i.e., demographic features (6), diseasespecific clinical markers (71), treatment-related features (17), laboratory and biomarkers (48), comorbidity and lifestyle factors (18), and other factors (15).

A closer look at the clinical features across diverse diseases reveals a consistent set of fundamental demographic features i.e., age and gender which are prevalent in nearly all studies<sup>85,86,91,111,112,115</sup>. Beyond demographic features, diseasespecific features also play critical role for disease-specific survival prediction. For instance, cancer-related studies invariably focus on tumor stage, histological type, and treatment specifics, underlining the critical role of disease-specific clinical markers in prognosis<sup>22,75</sup>.

Treatment-related features such as chemotherapy, radiotherapy, and immunotherapy, are particularly evident in cancer subtypes specific studies which reflect the profound influence of therapeutic interventions on survival outcomes<sup>86,98</sup>. Moreover, the recurrent inclusion of lifestyle and comorbidity factors ranging from smoking history and BMI to hypertension and diabetes across multiple diseases underlines their pervasive impact on prognostic modeling<sup>101,111</sup>. These lifestyle and comorbidity features show the complex relationship between individual health choices and their potential influence on survival outcomes.

# RQ VII: Feature engineering trends across data modalities and disease-specific survival predictors

This section addresses research question VII by investigating the application of feature engineering methods in survival prediction studies across a variety of diseases. This will help researchers to analyze and understand trends of feature engineering techniques in disease or endpoint specific survival prediction pipelines. Additionally, it delves into the trends in diverse feature engineering methods and their relevance to clinical and multiomics data modalities. This investigation aims to reveal trends and patterns in the dynamic interplay between feature engineering methods and the specific characteristics of different data modalities, and survival endpoints.

Table 6 illustrates 26 different feature engineering methods that have been utilized in diverse survival prediction studies. These methods are broadly categorized into five categories, namely supervised methods, incorporating L1 regularized Cox regression<sup>29</sup>, RSF algorithm<sup>29</sup>, Cox regression<sup>103</sup>, least absolute shrinkage and selection operator (lasso) regression<sup>120</sup>, cascaded Wx<sup>105</sup>, recursive feature elimination<sup>38</sup>, Boruta<sup>31</sup>, Akaike information criterion (AIC) regression<sup>114</sup>, variance<sup>72</sup>, lasso analysis<sup>40</sup>, multivariate regression<sup>40</sup>, Chi-squared<sup>118</sup>, mutual information<sup>118</sup>, and ANOVA<sup>39,118</sup>. Additionally, Network based methods include network based stratification (NBS)<sup>83</sup>, weighted correlation network analysis (WGCNA)<sup>86</sup> canonical correlation analyses (CCA)<sup>67</sup>, patient similarity networks<sup>38</sup>, and neighborhood component analysis (NCA)<sup>23</sup>. Dimensionality reduction methods include non-negative matrix factorization (NMF)<sup>40</sup>, autoencoders (AEs)<sup>28</sup>, variational autoencoders (VAEs)<sup>43</sup>, principal component analysis (PCA)<sup>39</sup>, and dominant effect of the cancer driver genes  $(DEOD)^{75,132}$ . Moreover, clustering methods comprise Kruskal-Wallis and Gaussian clustering<sup>131</sup>, hierarchical clustering<sup>82</sup>, and Guassian clustering<sup>131</sup>.

A comprehensive analysis of feature engineering methods across a range of disease-specific survival prediction studies

unveils that supervised methods, such as Cox regression, L1 regularized Cox regression, and RSF algorithm, have been prevalent in diseases like ASCVD, trauma, and ovarian cancer<sup>103, 120</sup>. On the other hand, network based methods including NBS and WGCNA, have been applied in diseases like KIRP, and hepatocellular carcinoma, which shows the significance of network structures in certain medical contexts<sup>86</sup>. Univariate analyses, including ANOVA, chi-squared, and univariate Cox regression, have been prevalent in diseases such as pancreatic cancer and heart failure, underscoring the significance of statistical testing in identifying relevant features<sup>71,118</sup>. Furthermore, dimensionality reduction methods such as PCA, and NMF have been consistently used across various diseases namely, ovarian cancer<sup>103</sup>, lower grade glioma<sup>80</sup>, colon adenocarcinoma<sup>39</sup>, bladder and breast cancers<sup>40,70</sup>. In addition, the potential of AEs, and VAEs have also been explored in diseases like glioblastoma multiforme, breast cancer, pancancer, and Lung Adenocarcinoma for feature integration and dimensionality reduction<sup>14,28,101</sup>.

While feature engineering methods exhibit specificity tailored to distinct diseases, their efficacy is influenced by the inherent characteristics of the utilized data. This raises the pertinent question of which particular feature engineering method proves most effective in the context of clinical and multiomics datasets. A thorough analysis of feature engineering methods and their applicability with respect to clinical and multiomics datasets reveals that methods like Cox regression, CCA, AIC, and ANOVA have been quite widely utilized in studies involving only clinical data<sup>29,67,114,118</sup>. These methods have been applied to clinical data for multiple reasons for instance, such methods are interpretable which is important to gain meaningful insights for healthcare professionals. Clinical data is always multifactorial, which means that multiple features of the data can lead to a specific event, and methods like ANOVA are quite efficient in analyzing such contributors. Although, such models have shown promising performance with clinical data, yet one of the drawbacks of such models is their inability to handle non-linear data which is the case in terms of multiomics data. Considering similar limitations, multiple methods such as cascaded wx<sup>105</sup>, RFI<sup>38</sup>, PSN<sup>31</sup>, NMF<sup>40</sup>, Boruta<sup>31</sup>, PCA<sup>82</sup> variance<sup>72</sup>, DEOD<sup>75</sup>, have been utilized to handle multiomics to capture important interactions among the features and to integrate cross modalities properly. Particularly, here methods such as AEs and VAEs play a significant role and recent studies also show a growing interest in using such methods for dimensionality reduction and feature integration by such methods for multiomics and clinical datasets i.e., AEs<sup>26,27,31,39,39,41-43,76,90</sup>, and VAEs<sup>28,89,100,106</sup>.

Although the selection of a feature engineering method is tied to the characteristics of the disease and the nature of the data, there is no significant evidence to suggest that it is substantially impacted by survival endpoints such as DFS, PFS, BC, and OS. This assumption arises due to the absence of a consistent pattern in feature engineering method selection across different survival endpoints. Studies, such

Study	Disease	Total	Features (Generic)
29	Atherosclerotic Cardiovascu- lar disease (ASCVD)	39	Height, Weight, Waist and Hip Circumference, Blood Pressure, B-Ultracound, Heart Rate, Hypertension, Prehypertension, Pulse Pressure Difference, Body Mass Index, Body Obesity Index, Waist to Hip Ratio, Composite Index Triglyceride, Blood Glucose Index, Fat Accumulation Product Index, Lipoprotein Binding Index, Atherosclerosis Index, Atherogenic Index of Plasma, Low High Density Lipoprotein Ratio, Bilirubin Composite Index, Family History of Diseases of Diabetes or ASCVD, Smoking, Alcohol Consumption, Fasting Blood Glucose, Triglyceride, High-Density Lipoprotein Cholesterol, Total Cholesterol, Low-density Lipoprotein Cholesterol, Diabetes, Fatty Liver, Blood Glucose Index, Fat Accumulation Product Index, Lipoprotein Binding Index, Atherosclerosis index, AIP, Low–high-density lipoprotein ratio and Bilirubin Composite Index
22	Localized Prostate Cancer	24	Prostate-specific Antigenes, Gleason Primary Score, Tumor Stage Expression Levels for NF2 and CDKN1B
30	Gastroesophageal Cancer	117	Biometric Variables, Past Medical History of Diseases, Tumor Diagnosis, cTNM Classification, Histology, Neoadjuvant Therapy, Time between Diagnosis and Resection, Type of Operation, Extent of Resection, Anatomical Reconstruction, Duration of Surgery, Intraoperative Complication, Blood Loss and Transfusion, Days on ICU and Ward, Postoperative Complications, pTNM Classification, Lymph Node Ratio, Grading, R status, Histology, Post-discharge Problems
81	Bladder Cancer	17	Gender, Median Age, Ethnicity, Smoking History, Initial Tumor stage, Neoadjuvant Chemotherapy Received, Histology, Pathology, Pathologic Complete Response, Smoking History, Pack Years, Body Mass Index, Hemotocrit, Urine cfDNA, Variant Allele Frequency, Inferred Tumor Mutational Burden, Tumor Fraction
85	Lymphoma	18	Sex, Age at Diagnosis, Ethnic, Medical Insurance, Ann Arbor Stage, Pathological Type, B symptoms, Surgery, Radiotherapy, Chemotherapy, Targeted Therapy, Immunotherapy, LDH, β2-microglobulin, Platelet, Lymphocyte, Albumin Globulin ratio and C reactive protein
75	Colon Cancer	7	Age, Sex, AJCC stage, Prognostic Information such as Alive, Deceased, Disease Free and Recurrence
86	Hepatocellular Carcinoma	24	Age, Gender, ALT, Main Tumor Size, Multinodular, Cirrhosis, TNM stage, BCLC stage, CLIP stage, Tumor Grade, TMB, Stromal Score, Immune Score, ESTIMATEScore, Risk Score, CNLC stage, Hepatitis B, Lymph node invasion, Vascular Invasion, Perineural Invasion, Albumin, AFP, CEA and CA199
95	Non-small Cell Lung Cancer	6	Histology, Gender, Age, Pathological Staging, DFS, and Smoking Status related features
98	Breast Cancer	25	Age at Diagnosis, Tumor Size, Tumor Stage, Lymph Nodes, Examined Positive Neoplasm, Histologic Grade, Histological type, ER Status, PR Status, HER2 SNP6 State, Type of Treatment, The Patient Received Survival Status and Time, Inferred Menopausal State, Overall survival, HER2 SNP6 State, Treatment and Patients Vital Status
118	Heart Failure	13	Age, Anaemia, High Blood Pressure, Creatinine Phosphokinase, Diabetes, Ejection Fraction, Sex, Platelets, Serum Creatinine, Serum Sodium, Smoking, Time Follow up Period and Death Event
67	Metastatic Breast Cancer	10	Age at Diagnosis, Mean age, Molecular classification (Luminal, Triple-negative), De novo Metastasis, Number of Metastatic Sites, Visceral Metastases, Adjuvant Chemotherapy, Adjuvant Radiotherapy, Adjuvant Endocrine Therapy and Previous Endocrine Therapy
96	Non-small Lung Cancer	11	Age, Sex, Tumor, Volume, Primary Diagnosis, Prior Malignacy, Synchronous Malignancy, Pathological Stage , Staging Tumor, Staging Lymph Nodes, Staging Metastasis, No. of Pack-years Smoked
66	Nasopharyngeal Carcinoma	17	Age, Stage, Sex, Ethnicity, Marriage, Occupation, Pathological, Transfer Information, Radiotherapy, Chemical Therapy, Targeted Therapy, EBV, BQ, LAR, NLR and PLR
112	Cardiovascular	8	Age, Age Groups, Sex, Region of Residence, Number of Charlson Comorbidities, Charlson comorbidities, Lab Test Results(LDL-cholesterol, Blood Glucose, eGFR, HbA1c, At least one Lab Test), Features related to Medications
78	Esophageal Carcinoma	3	Vital Status, Days to Death and Days to Last Follow up
91	Glioblastoma multiforme	9	Age, Gender, Diagnosis Method, Treatment History, Karnofsky Score, Performance Score, Radiation Therapy, Duration of Survival and Death Status
115	Cardiovascular Disease	12	Age, Sex, Body Mass Index, Smoking Status, Systolic and Diastolic Blood Pressure, Current Smoker, Total Cholestrol, HDL Cholestrol, Triglycerides, Lipid Lowering Drug Dose, Antihypertensive Drug Use and Median Follow-up Time
111	Atherosclerosis	33	Age, Albumin/Creatinine Ratio, BMI, Cholesterol, Diabetes, Educational Status, Family History of Heart Diseases, Gender, HDL, Hyperlipidemia, Hypertension, Income Category, LDL, Mean Diastolic and Systolic Blood Pressure, Metabolic Syndrome, Smoking in Past Years, Statin Use, Triglycerides, Minutes Walking Per Week, C Reactive Protein, D Dimer, Factor VIII, Fibrinogen Antigen, Homocysteine, Interleukin-6, Plasmin Antiplasmin, Pericardial Fat Deposition, Coronory Artery Calcium Score, Left Ventricular Area and Left Ventricular Ejection Fraction
72	Multiple Cancer Subtypes	3	Age, Overall Survival time, Status
94	Prostate Cancer	4	Age at Diagnosis, Clinical Tumor stage(T1(a-c),T2(a-c), T3(a-b),T4), NA Gleason Score and Preoperative PSA
119	Liver Trans- plantation	97	52 Donor and 45 Liver Recipient Characteristics, Unique Encrypted Person Id, Unique Encrypted Donor Id, Candidate Listing Center, OPO Serving, Transplant Center, Transplant Date, Graft Failure Date, Cohort Censoring Date, Death Date, Graft Follow up Date, Age, Gender, Race, Ethnicity, Socioeconomic Status and Education Level, Smoking History, Alcohol Consumption, Physical Activity Level, Cocaine or Other Drug History, Blood Type, Etiology (Cause of Disease), Laboratory Measurements for Arginine, Serum Creatinine, Serum Sodium, Total Bilirubin
26	Pancreatic Adenocarci- noma (PAAD)	7	Sex, Grade, AJCC Cancer stage, Smoking history, Treatment Outcome, Age, Primary Site
77	Colon Cancer	7	Gender, Survival Status, Survival Time, TNM Stage, Age at Initial Diagnosis

#### Table 5. Diverse collection of clinical features utilized in various survival prediction studies.

> $as^{95}$ ,  $as^{39}$ , and  $as^{40}$ , demonstrate a varied use of feature engineering techniques irrespective of the specific survival endpoints (DFS, PFS, BC, or OS). This lack of uniformity implies that feature engineering method selection is driven more by the unique characteristics of the data and disease than by the nature of the survival endpoint itself.

Table 6. Diverse feature engineering methods for survival prediction.

Method Name	Studios	— metrics							
	29								
L1 regularized Cox regression	29	Library	Language	Models					
RSF algorithm	29	scikit- survival <sup>133</sup>	Python	Cox-PH, Penalized Cox- PH, RSF, Kaplan-Meier,					
Cox regression	29,103			Gradient boosting survival					
Network-Based Stratification (NBS) for data integration	83	L ifolinos <sup>134</sup>	Puthon	machine Kaplan MajarEittar					
Weighted correlation network analysis (WGCNA)	86	Litelines	Python	CoxTimeVaryingFitter, Survival regression, D crete survival mode					
Canonical correlation analyses (CCA)	67			Piecewise exponential models					
Least Absolute Shrinkage and Selection Operator (lasso) regression modeling	120	survival <sup>135</sup>	R	Survival regression, Cox- PH, accelerated time failure (AFT) models, Competing risk analysis,					
Cascaded Wx	105	Statsmodels <sup>13</sup>	<sup>36</sup> Python	PHReg, AFT models					
Recursive feature elimination	38								
Patient similarity networks	38	127							
Boruta	31	Pycox <sup>157</sup>	Python	Continuous time models such as Cox-Time, CoxCC,					
Akaike Information Criterion (AIC) regression	114			PCHazard and DeepSurv, Discrete time models such as Nnet-survival, probabil-					
Kruskal-Wallis and Gaussian clustering	131			ity mass function, Deep- Hit, multitask logistic re- gression, and BCEsurv					
Variance	72	Pysurvival <sup>138</sup>	Python	CoxPH, RSF, Kaplan-					
Non-negative matrix factorization (NMF)	40			Meier, Survival Support Vector Machine, multi- task logistic regression,					
Lasso analysis	40			Parametric models like exponential, Weibull,					
Multivariate regression	40			Gompertz, log logistic, and					
PCA	31, 39, 82, 103	flexsurv <sup>139</sup>	R	Parametric survival models					
ANOVA	39,118			(e.g., Weibull, Exponential)					
Chi-squared	118								
Mutual information	118	mlr3proba140	R	Density estimation mea- sures Cox-PH flexible					
Hierarchical clustering	77,82			spline models, penalized re-					
Neighborhood component analysis (NCA)	23			gression, RSF, van Belle support vector machine, gradient boostinf machine					
DEOD	75			Time					
Variational autoencoders	28, 89, 100, 101, 106	rstpm2 <sup>141</sup>	R	Restricted Mean Survival					
Autoencoders	26, 27, 31, 39, 41–43, 76, 90	_		specific Hazard Models. Fine-Gray Model (Compet- ing Risks)					
		survex <sup>142</sup>	R	Local and global explana-					

Table 7. Survival analysis libraries, models, and evaluation

**Evaluation Metrics** Concordance Index

(C-index). Integrated Brier Score

Concordance Index

Hazard Ratios, Log-

likelihood, Akaike In-

formation Criterion

Hazard Ratios, Loglikelihood, Akaike Information Criterion

Concordance Index. integrated and admin-

istrative Brier Score, time dependent con-

cordance index, neg-

ative and integrated

bionomial log likeli-

Concordance Index

(C-index), Integrated

Hazard Ratios, Loglikelihood, Akaike In-

formation Criterion

C-index, time depen-

dent AUC, log-loss,

integrated log loss,

Brier and integrated Brier score,

IBS, Time-dependent

ROC curves, Grays

Test for Equality of Cumulative Incidence

Schmid score

Functions

None

β,

and

Brier Score

(C-index)

(AIC)

(AIC)

hood

(AIC) Houwelingen's

On the basis of various trends and patterns it can be con-

tions for survival prediction

models

cluded that for heart diseases, univariate analyses and supervised feature engineering methods have been utilized. Conversely, in terms of cancer subtypes a mixture of dimensionality reduction methods is observed with a recent trend toward the AEs. In terms of survival datasets, the prime focus has been to use supervised methods for clinical data and multiple dimensionality reduction methods for multiomics data. Moreover, there are no conclusive remarks that feature engineering methods get affected by the survival endpoints, as the current literature also suggests a varied use of feature engineering methods regardless of the survival endpoints.

### RQ VIII: Survival Prediction Methods Insights and Distribution Across Disease Types and Survival Endpoints

In pursuit of addressing research question VIII, this section presents an overview and insights about statistical, ML, and DL algorithms that have been utilized in existing survival prediction pipelines. It succinctly examines their emerging trends across diseases and survival endpoints. This exploration aims to empower researchers in identifying gaps within disease-specific and survival endpoint-focused studies, ultimately contributing to the enhancement of survival predictive pipelines.

Table 8 provides information about 44 diseases and the corresponding survival prediction algorithms utilized in these diseases. A deeper analysis of Table 8 shows that Cox-PH and lasso Cox-PH models have been extensively utilized for disease specific survival prediction i.e., ASCVD<sup>29,111</sup>, bladder cancer<sup>40,82</sup>, colorectal cancer<sup>74–77</sup>, hepatocellular carcinoma<sup>43,86,87</sup>, ovarian cancer<sup>88–90,103</sup>, lung adenocarcinoma<sup>101</sup>, heart failure<sup>118</sup>, HER2-negative metastatic breast cancer<sup>67</sup>, pancreatic cancer<sup>26,71</sup>, trauma<sup>120</sup>, nasopharyngeal carcinoma<sup>66</sup>, triple-negative breast cancer<sup>68</sup>, lymphoma<sup>85</sup>, breast cancer<sup>40,81,82</sup>, ovarian cancer<sup>88–90,103</sup>, and lower-grade glioma<sup>80</sup>, cardiovascular disease<sup>112,114–117</sup>, invasive ductal carcinoma<sup>70</sup>, liver transplantation<sup>119</sup>, gastric cancer<sup>42</sup>, lung cancer<sup>27</sup>, esophageal squamous cell carcinoma<sup>79</sup>, glioma<sup>69</sup>, and liver cancer<sup>41</sup>. RSF has been employed in 13 studies for 6 diseases namely, ASCVD<sup>29</sup>, bladder cancer<sup>82</sup>, gastrointestinal cancer<sup>30</sup>, cervical cancer<sup>73</sup>, liver transplantation<sup>119</sup>, and heart failure<sup>118</sup>. DL model DeepSurv, has been utilized in 5 studies related to gastrointestinal cancer<sup>30</sup>, ASCVD<sup>111</sup>, NSCLC<sup>97</sup>. On the other hand, in the analyzed survival predictive pipelines less frequently utilized methods are i.e., survival SVM<sup>79,95,120</sup>, partial logistic regression<sup>70,75</sup>, log hazard net<sup>75, 104</sup>, boosting<sup>41, 112</sup>, stepCox<sup>86</sup>, elastic net<sup>95</sup>, CNNcox<sup>104</sup>, DeepOmix<sup>104</sup>, ordinal Cox-PH<sup>78</sup>, DeepHit<sup>112</sup>, and linear multitask logistic regression (MTLR)<sup>112</sup>.

Furthermore, supplementary Table S3 provides details about predictors distribution with respect to survival endpoints. A detailed analysis reveals, out of 74 predictors, 31, 8, 1, and 6 models have been utilized for OS, DFS, PFS, and BC survival endpoints respectively. Unlike disease-specific predictors, here a mixture of methods is utilized and no particular trend **Table 8.** Distribution of survival predictors across diverse diseases.

Studies	Disease	Predictor
29,111	ASCVD	Cox-PH, RSF, MTLR, Deepsurv
14.02		neural network, lasso Cox-PH
14,83	KIRP	GeneNet, ANNs
22,94	Prostate cancer	Coherent Voting Network (CVN),
		Best Linear Unbiased Prediction
30		(BLUP)
20	Gastrointestinal cancer	DeepSurv, MTLR, Gompertz model,
68	Tripple pagative breast	KSF lasso Cox PH
	cancer	lasso Cox-FII
40, 81, 82	Bladder cancer	Cox-PH, RSF, CoxNet, and transfer
		learning-based CoxNet
85	Lymphoma	lasso-Cox-PH
74–77	Colon cancer	Loghazard Net, partial logistic
		regression, Cox-PH
43,86,87	Hepatocellular carcinoma	Stepwise Cox (StepCox),
88 00 102		SurvivalSVM, Cox-PH, CoxNet
88-90,103	Ovarian cancer	Cox-PH, Cox-Time, and DeepSurv
95-97	NECLO	with consensus training
15-71	NSCLC	SVM, Elastic net and Cox-PH, CNN
28	Multiple cancors	anu AININ A NIN
23,90,98,100	Breast cancer	CoxNet Cox-PH Cox-Time and
	Breast cancer	DeepSury with consensus training
		Loghazard Net, partial logistic
		regression
101	Lung adenocarcinoma	Cox-PH, and lasso Cox-PH
24,72,104–10	<sup>8,131</sup> Pancancer	Survival neural network, CNN-Cox,
		Cox-PH, DeepOmix, lasso and group
100		penalized Cox-PH, VAE based NN
119	Colorectal cancer	Lasso Cox-PH
67	Heart failure	Cox-PH, RSF
07	HER2-negative metastatic	Cox-PH
26,71	Pancreatic cancer	Cox-PH 12 regularized regression
120	Trauma	RF. SVM for outcome prediction
66	Nasophrngeal carcinoma	Cox-PH
112, 114–117	Cardiovascular disease	Survival outcome prediction based on
		naive Bayes, ANNs, and SVM,
		Logistic regression and XGboost.
		Survival prediction: Cox-PH,
		survival XGboost, DeepHit,
		DeepSurv, Cox-PH, Linear MTLR,
113	COVID-19	anu KSF SVM
38	Neuroblastoma	Deep neural network (DNN)
70	Invasive ductal carcinoma	Multivariate Cox two way stepwise
		regression
78	Stomach, Esophageal	Bidirectional LSTM, ordinal Cox
	carcinoma and Ovarian	model network and auxiliary loss
00	serous cystadenocarcinoma	_
80	Lower grade glioma	lasso Cox-PH
31 00_03_102	Renal cell carcinoma	Cox-PH
90-93,102	Glioblastoma	Cox-PH, CoxNet, SVM and Cox-PH,
73	Cornical concer	Iasso Cox-PH
84	Ovarian and breast cancer	Kor, and Cox-PH
119	Liver transplantation	RSF Cox-PH and partial logistic
	Error transplantation	artificial neural networks (PLANN)
39	Lung adenocarcinoma	
42	Gastric cancer	lasso, univariate and multi-variate
		Cox-PH
27	lung cancer	Cox-nnet
79	esophageal squamous cell	Support vector machine, K-means
60	carcinoma	clustering
69 41	Glioma	Cox regression
	Liver cancer	XGBoost for subtype classification,
		and Cox-PH for survival prediction

Publication

exists. To provide high-level overview of multiple methods that have been utilized in all four survival endpoints we have provided a graphical representation of methods in Figure 7.

It can be seen in Figure 7, diverse types of methods that have been utilized in survival predictive pipelines can be categorized into three different categories i.e., statistical, ML, and DL. Statistical methods are broadly classified into three different categories i.e., parametric, semi-parametric, and non-parametric models. Parametric methods make assumptions about the survival time distribution<sup>122,143</sup>. Parametric methods include exponential, Weibull, log-normal, Weibull, gamma models, and so on<sup>143,144</sup>. Comparatively, semiparametric methods make no assumptions about the shape of the baseline hazard function (non-parametric). Rather, these methods assume a specific functional form for the effect of covariates (parametric)<sup>145</sup>. In comparison, non-parametric methods do not take into account assumptions about the underlying distribution of survival times and the shape of the hazard function. These methods include Kalpan-Meier, Nelson-Aalen, Breslow, Gehan-Eilcoxon, and life table methods<sup>146</sup>. Statistical methods have certain disadvantages with multiomics based survival prediction<sup>59</sup>. For instance, statistical models assume linear relationships among variables and fail to capture complex and non-linear data patterns<sup>147</sup>. These methods perform poorly on high dimensional data where the number of features is larger than the number of samples. This specific gap is filled by the emergence of AI based models. Various ML models are utilized for survival analysis such as random survival forest<sup>148</sup>, and boosting-based methods<sup>149</sup>. Belle et al., Shivasmy et al., and Khan et al., 150-152 proposed ranking and regression-based survival SVM for survival prediction while handling right censored data. Particularly, survival SVM is used in three ways for survival prediction i.e., ranking, regression, and combined. Ishwaran et al.,<sup>148</sup> proposed RSF where log-rank test is utilized for the splitting as compared to the Gini impurity of the classical random forest models.

DL methods are utilized in two ways to model survival prediction tasks i.e., continuous and discrete time. Models like CoxCC and time<sup>137</sup>, piecewise constant hazard or PEANN<sup>153</sup>, and DeepSruv<sup>154</sup> are utilized for continuous survival time prediction. Whereas, Nnet-survival<sup>155</sup>, Nnet-survival probability mass function (PMF)<sup>156</sup>, DeepHit and DeepHit Single<sup>157</sup>, multi-task logistic regression (MTLR)<sup>158,159</sup>, and BCESurv<sup>160</sup> are utilized to predict survival in a discrete-time setting.

# RQ IX: Open source tools and libraries potential for development of survival prediction pipelines

Following the objective research question IX, this section summarizes details of open-source libraries and source codes of existing survival predictors. This comprehensive information will facilitate researchers to build upon existing work, fostering a collaborative environment and accelerating the development of robust and effective survival prediction models.

Table 9 presents an overview of open-source survival

83	Kidney Papillary, Renal Cell Carcinoma (KIRP)	GeneNet	Link
22	Localized prostate cancer	Coherent Voting Network (CVN)	Link
14	GBM, KRCCC, LSCC, BIC	ANNs for binary survival class prediction	Link
103	Ovarian Cancer	DT, RF, and ANN	Link
95	Non-small Cell Lung Cancer	Two layer SVM	Link
28	Pancancer	ANN	Link
24	Pancancer	Survival neural network	Link
109	Colorectal cancer	Lasso penalized cox model	Link
118	Heart failure	Two-way survival prediction	Link
96	Non-small cell lung cancer	Elastic net and cox proportional hazard model	Link
105	Pancancer	CNN and a cox model (CNN-Cox)	Link
38	Neuroblastoma	Deep neural network (DNN)	Link
74	Breast cancer	Loghazard Net	Link
90	Glioblastoma, ovary and breast cancers	CoxNet	Link
91	Glioblastoma multiforme	Cox regression	Link
111	Atherosclerosis	Various models	Link
116	Cardiovascular disease	DeepSur, Cox-PH, RSF	Link
131	Pancancer	Cox-PH model	Link
72	8 cancer subtypes	DeepOmix based on DNN	Link
82	Bladder cancer	Cox regression, deep cox neural network	Link
89	Ovarian cancer	Cox-PH regression	Link
84	Ovarian, lung, kidney, and pancreatic cancer	Various survival models	Link
119	Liver transplantation	RSF, Cox-PH, PLANN	Link
27	Lung adenocarcinoma	Cox-nnet	Link
100	Breast cancer	DNN and cox proportional hazard model	Link
94	Prostate cancer	BLUP	Link
23	Breast cancer	Deep neural network	Link
106	Pancancer	Deep Neural network	Link

Table 9.	Summary of open-sou	arce survival	prediction
methods i	in existing studies.		

Disease

Approach

Source Code



Figure 7. Hierarchal illustration of survival prediction methods under three different categories.

prediction models. Among the 74 distinct survival prediction studies, only 26 have provided publicly accessible source code. Among these studies, 6 studies have utilized  $R^{91,94,96,103,109,119}$  and 20 have opted for Python<sup>14,24,28,38,72,74,82,83,89,90,95,100,105,111,116,118,131</sup>

<sup>23,27,106</sup>. A comprehensive analysis of open source codes reveals that a majority of these tools have been developed from scratch without utilizing any specific survival prediction library<sup>14,28,83,95</sup>.

Approximately 10 different survival prediction packages or libraries have been developed. Each library offers a diverse set of preimplemented statistical, ML, and DL survival prediction models. For instance, Pycox<sup>137</sup> primarily focuses on continuous and discrete DL survival prediction models such as CoxTime, CoxCC, MTLR, and so on. Lifelines<sup>134</sup>, scikit-survival<sup>133</sup>, and pysurvival<sup>138</sup> cover a wide range of statistical and ML survival prediction models like Cox-PH, RSF, survival support vector machine, and gradient boosting survival<sup>133, 134, 138</sup>.

Notably, addressing the lack of interpretability or explainability in the previously discussed libraries, Spytek et al.<sup>142</sup> introduced Survex. This library allows researchers to analyze the features responsible for a specific event by offering different methods for both local and global explanations of various survival prediction models.

The selection of a specific library is inherently subjective and depends on factors such as the preferred development platform, choice of survival prediction models, and the specific research question in hand. Therefore, recommendations are made based on the number of survival prediction models and evaluation measures each library offers. For Python, Lifelines<sup>134</sup> and Pycox<sup>137</sup> are recommended, with Lifelines<sup>134</sup> providing a diverse range of statistical and ML models, while Pycox<sup>137</sup> is specialized in DL models. Additionally, for R, mlr3proba<sup>140</sup> is recommended, as it offers a variety of statistical and ML models for survival prediction. Ultimately, selecting a library aligned with individual research needs not only streamlines the development process but also contributes to the overall reliability of survival prediction models.

# RQ X: Strategies for assessing survival predictors: unveiling common evaluation measures

The main objective of this section is to provide a concise overview of research question X, which focuses on the commonly employed evaluation measures for survival predictive pipelines.

Table 10 shows a compilation of 18 distinct evaluation measures that have been commonly used to evaluate survival prediction pipelines. The survival prediction pipelines can be categorized into two distinct classes namely survival outcome prediction and survival prediction. Details related to these categories is provided in the background section. Out of 18 evaluation measures mentioned in Table 10, a set of 10 evaluation measures have been employed to assess the performance of survival outcome prediction models. In addition to the

Task	Evaluation Measure	Count	References	Advantages
	C-index	43	22, 29, 83	Robust, measures discrim- inatory power. Less sen- sitive to censoring com- pared to other metrics.
	BS	7	111, 116, 119	Measures accuracy of pre- dicted survival probabili- ties.
	IBS	5	30, 98, 116	Considers entire survival time distribution.
liction	Log Rank P-value	9	28,31,68,91	Tests differences in sur- vival experiences.
val Preo	DCA	1	66	Accounts for clinical con- sequences.
Surviv	Kappa	3	22, 83, 107	Measures agreement be- yond chance.
	TD-ROC	2	67,68	Time-dependent evalua- tion of ROC.
	AUC-pval	1	22	Evaluates AUC signifi- cance.
	Odds ratio	1	22	Measures association be- tween groups.
	Likelihood Ratio	1	77	Helps in understanding the odds of a predicted
				event occurring compared to the odds of it not occur- ring.
	AUC-ROC	21	14,22,29	Provides a comprehensive view of the model's per- formance across various threshold values.
	Accuracy	12	14,75	Simple and easy to under- stand, providing an over- all measure of correct pre- dictions.
	Precision	6	14,67,81,98	Useful when the cost of false positives is high, as it focuses on the accuracy of positive predictions.
	Recall	6	14,67,81,98	Emphasizes the ability of the model to capture all positive instances, impor- tant for sensitive scenar- ios.
ion	MCC	1	98	
<b>Dutcome Predict</b>	F1-Score	2	38,114	Harmonizes precision and recall, making it useful when there is a trade-off between false positives and false negatives.
Survival	PPV	1	81,114	Focuses on the proportion of true positives among positive predictions, pro- viding insights into predic- tion accuracy.
	NPV	1	81,114	Focuses on the proportion of true negatives among negative predictions, pro- viding insights into predic- tion accuracy.

**Table 10.** A summary of evaluation measures used insurvival prediction and survival outcome prediction pipelines.







Figure 9. Publisher-wise distribution of articles.

aforementioned measures, 8 other evaluation measures have been utilized to assess the performance of survival prediction models.

In survival prediction category based evaluation measures the objective is to capture two distinct characteristics namely, discrimination and calibration. Specifically, calibration refers to how well the predicted probabilities of survival align with the actual observed survival rates over time. Under this paradigm most widely used evaluation measures are BS, IBS, TD-ROC, and DCA. Discrimination paradigm based evaluation measures capture differentiation between individuals with different survival times. Under this paradigm most widely used measures are C-index, AUC-ROC, and likelihood ratio.

On the other hand objective of survival outcome prediction evaluation measures is to assess diverse characteristics of a model i.e., efficacy of the model, overall accurate predictions, biasness towards type I or type II errors. Specifically, accuracy and F1 score are used to measure overall accurate predictions, precision, and recall examine the model's biasness with respect to type I and type II errors. Additionally, MCC provides a comprehensive assessment, taking into account overall accurate predictions, and errors. In addition, AUC-ROC assesses the predictive potential of a model by analyzing the true positive rate (TPR) and true negative rate (TNR) at different thresholds.

# RQ XI: Publisher and journal-wise distribution of research papers

This section addresses research question XI by presenting the distribution of survival prediction literature across diverse journals and publishers. Overall, this analysis not only enables researchers to strategically position their work but also offers opportunities for interdisciplinary collaboration, promoting a more interconnected and dynamic research landscape within the domain of survival prediction.

In Figure 8 and 9, the distribution of survival prediction literature is presented based on journals and publishers. The studies have been published in 16 different publishers, including but not limited to Springer, Elsevier, Oxford Press, and BioMed Central. Notably, around 30 out of 74 survival prediction studies have been disseminated through Springer, and BioMed Central. Furthermore, Elsevier has contributed to the field by publishing 10 relevant papers in recent years. Particularly, these studies have been published in more than 50 different conferences/journals, which shows the diversity of the survival prediction landscape.

## Discussion

The field of disease survival prediction has become a pivotal aspect of effective healthcare, especially within the domain of precision medicine. Recognizing the significant variability present among patients within specific diseases, there is an increasing demand and development for disease specific survival predictors. Our analysis reveals that researchers place a profound emphasis on predicting survival in cancer as compared to other diseases, and there are compelling reasons behind this focus. First, cancer exhibits significant variability from one patient to another as compared to other diseases, which highlights the imperative need for cancer survival prediction to explore and comprehend the heterogeneity of cancer. Second, cancer is a leading cause of death worldwide, and effective survival prediction can aid in early detection and intervention, potentially saving lives. Third, a huge amount of data sources are developed to make cancer-related data publicly available to accelerate and optimize cancer-related research.

Furthermore, to analyze the trajectory of the disease, researchers place great focus on studying different survival endpoints that suit the respective research setting i.e., treatment, progression, recurrence, and death. Among 4 different survival endpoints i.e., OS, DFS, BC, and PFS, OS is often emphasized more in survival prediction studies. Despite the prime focus on OS, the significance of other survival endpoints in understanding disease trajectories cannot be understated. These survival endpoints help to analyze different characteristics of diseases such as understanding treatment efficacy and durability, treatments that not only extend life but also effectively manage the course of the illness, and markers responsible for disease recurrence. The lack of research in other survival endpoints opens up new research avenues for the AI experts to develop novel methods that can help explore various characteristics related to disease.

Although both public and private databases have been utilized in survival prediction studies, yet the preference for public databases stems from their accessibility and the wealth of information they provide. For instance, TCGA<sup>17</sup> offers a vast array of genomic and clinical data across different cancer types. This invaluable resource aids researchers in developing accurate survival prediction models. Likewise, GDC<sup>18</sup> and GEO<sup>130</sup> offer comprehensive datasets that encompass a wide range of diseases, making them appealing choices for various research endeavors. Furthermore, a crucial observation regarding private data sources is that they are not universally accessible. This argument is supported by the limited accessibility of omics datasets related to cardiovascular diseases. Despite a singular study employing omics data for survival prediction in cardiovascular diseases, the challenge lies in the difficulty of retrieving the original data. Authors often refrain from sharing their datasets, and obtaining access to databases requires extensive proposals, adding a layer of complexity to the development of novel survival prediction pipelines for cardiovascular diseases. This obstacle may impede the advancement of innovative survival prediction pipelines for cardiovascular disease.

Overall, the use of omics and clinical data in survival prediction tools marks a significant stride toward precision medicine. The distribution of omics types in survival prediction studies reveals a preference for mRNA, methylation, microRNA, and CNV across various cancer subtypes. In addition, the limited number of multiomics based survival prediction studies in cardiovascular diseases hinders definitive conclusions

on the importance of specific omics types. Disease-specific patterns highlight the importance of tailored clinical markers, prominently seen in cancer studies with a focus on tumor stage and histological type. Treatment-related features, notably chemotherapy and radiotherapy, underscore the impact of therapeutic interventions on survival predictions. Moreover, clinical features along with omics data with diverse molecular aspects are utilized together to improve the performance of survival prediction models. Diverse survival prediction research accentuates the pivotal role of leveraging patient information, such as medical history, demographics, diseaserelated features, and diagnostic records. This trend reflects an increasing recognition of the potential of clinical data in not only understanding disease progression but also in guiding personalized treatment strategies and enhancing patient care. A recent benchmark study on survival prediction models with multiomics and clinical data also shows the significant role of clinical data in survival prediction across multiple cancer subtypes<sup>45</sup>.

In addition, our analysis reveals that increasing the total number of data modalities does not necessarily offer improved survival predictions, yet data modalities are quite specific to the disease and survival endpoints. Therefore, the selection of data modalities should be made very carefully as rather than improving the overall performance it can induce undesirable noise in the analysis.

One of the common problems in survival analysis is data censoring. Censoring arises when there is incomplete information about the time points and/or events of some subjects in a study. There are different types of censoring i.e. I) Right Censoring is the most common type of data censoring, where an event does not occur for some subjects by the end of study or by the last time point at which data is collected. For example, a subject withdraws from the study or there is a lost follow up for a specific subject II) Left Censoring is the least common type of censoring where the event may occur before the start of the study or during the data collection phase. III) Interval Censoring arises when the event of interest occurs in a time interval but the exact time point is not known. In survival analysis, three assumptions are taken into account to infer censored data i.e., II) Independent Censoring: assumes that the censoring times for multiple subjects are independent of each other. II) Random censoring assumes that the time t at which individuals are censored must be random and the failure rate for subjects who are censored is assumed to be equal to the failure rate for subjects who remained in the risk set who are not censored. III) Non-informative censoring occurs if the distribution of survival times (T) provides no information about the distribution of censorship times (C), and vice versa. Although, data censoring is quite important in terms of survival prediction, yet it has been discussed and dealt with properly in the existing studies. We recommend to incorporate comprehensive details of data censoring in future survival prediction studies. Particularly details on how each type of data censoring is handled should not be neglected.

Our analysis of the utilization of feature engineering methods raises two crucial points. First, even though a plethora of methods have been already tested for various survival prediction studies, autoencoder based methods tend to reduce the dimensionality of omics data modalities more efficiently. In addition, the rest of the methods work much better with clinical features. The success of feature engineering approaches is contingent upon the chosen technique with the inherent properties of the data. This highlights the importance of large-scale benchmark studies in guiding the selection of feature engineering strategies for the development of accurate predictive pipelines.

With an aim to evaluate the performance of predictive pipelines, diverse types of evaluation measures have been developed. Each evaluation measure addresses a specific aspect of survival prediction models, precluding the possibility of any single metric being universally ideal for a comprehensive evaluation of survival prediction. For instance, Cindex estimates the robustness and discriminatory power of the survival prediction model. In addition, BS and IBS measure the accuracy of a model on time distribution. Moreover, log-rank p-value evaluates the potential of the model by testing the differences in different survival groups. Although these measures are the most commonly utilized, there are diverse other evaluation measures for similar purposes i.e., restricted mean survival time (RMST), odds ratio<sup>22</sup>, Kappa for inter-rater reliability<sup>107</sup>, integrated absolute error (IAE), integrated square error (ISE), mean absolute error (MAE), integrated AUC (IAUC) time-dependent integrated discrimination improvement, and time-dependent net reclassification improvement (NRI). Furthermore, while these individual measures provide valuable insights, it is noteworthy to mention that their collective application offers a more comprehensive evaluation. Therefore, we recommend utilizing multiple evaluation measures to assess discrimination and calibration of survival prediction models.

### Methodology

This section explains different steps or stages of preferred reporting items for systematic review and meta-analyses (PRISMA) strategy<sup>161</sup>, which is used to gather relevant papers on survival analysis. Figure 10 provides a visual representation of various stages form PRISMA that are summarised in the following subsections.

#### Search Strategy

In Figure 10, the identification stage illustrates combinations of different keywords that are used to search research articles. The keywords block has two different types of operators ' $\wedge$ ' and ' $\vee$ ' operators. On the basis of these operators one keyword from each block is selected and various search queries are formulated such as, "SURVIVAL PREDICTION AND AI AND OMICS", "SURVIVAL PREDICTION AND AI AND Multiomics", "SURVIVAL Machine Learning AND OMICS", and so on. These queries are utilized in literature search en-



**Figure 10.** A step-by-step process for articles search and their inclusion or exclusion criteria to generate a set of studies for further in-depth trends analysis

gines like lens (https://www.lens.org/), and Google Scholar for literature search from Jan 2020 to Jul 2023.

#### **Screening Strategy**

With an aim to retain literature related to survival prediction, two different screenings are performed on the basis of the following criteria;

- Articles that do not make use of only image-based datasets for survival prediction.
- Articles that do not make use of ML, DL, or statistical methods for survival prediction.
- Articles with closed access.

Initially, guided by the title and abstract of the articles, more than 900 studies are discarded. Subsequently, at the final step, based on a comprehensive review of the full text a second screening is performed, resulting in the exclusion of an additional 20 studies. Ultimately, 74 papers are selected for the final comparison and discussion of survival prediction.

#### References

1. Haendel, M. *et al.* How many rare diseases are there? *Nat. reviews drug discovery* **19**, 77–78 (2020).

- **2.** Jamison, D. T. Disease control priorities: improving health and reducing poverty. *The Lancet* **391**, e11–e14 (2018).
- **3.** World Health Organization. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/ detail/the-top-10-causes-of-death (2020). Accessed: January 4, 2024.
- **4.** Sellin, J. A. Does one size fit all? patents, the right to health and access to medicines. *Neth. Int. Law Rev.* **62**, 445–473 (2015).
- Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. *Nat. biotechnology* 30, 679–692 (2012).
- 6. Kosorok, M. R. & Laber, E. B. Precision medicine. Annu. review statistics its application 6, 263–286 (2019).
- 7. Ashley, E. A. Towards precision medicine. *Nat. Rev. Genet.* 17, 507–522 (2016).
- Farrokhi, M. *et al.* Role of precision medicine and personalized medicine in the treatment of diseases. *Kindle* 3, 1–164 (2023).
- **9.** Kamps, R. *et al.* Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. *Int. journal molecular sciences* **18**, 308 (2017).

- Billheimer, D., Gerner, E. W., McLaren, C. E. & LaFleur, B. Combined benefit of prediction and treatment: a criterion for evaluating clinical prediction models. *Cancer informatics* 13, CIN–S13780 (2014).
- **11.** Tsimberidou, A.-M. *et al.* Long-term overall survival and prognostic score predicting survival: the impact study in precision medicine. *J. Hematol. & Oncol.* **12**, 1–12 (2019).
- Sarma, A., Calfee, C. S. & Ware, L. B. Biomarkers and precision medicine: state of the art. *Critical care clinics* 36, 155–165 (2020).
- **13.** Chen, Y.-C., Lee, U. J., Tsai, C.-A. & Chen, J. J. Development of predictive signatures for treatment selection in precision medicine with survival outcomes. *Pharm. Stat.* **17**, 105–116 (2018).
- 14. Hao, Y., Jing, X.-Y. & Sun, Q. Cancer survival prediction by learning comprehensive deep feature representation for multiple types of genetic data. (2023).
- Glare, P. *et al.* A systematic review of physicians' survival predictions in terminally ill cancer patients. *Bmj* 327, 195 (2003).
- **16.** Carobbio, A. *et al.* A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. *Blood cancer journal* **10**, 100 (2020).
- Tomczak, K., Czerwińska, P. & Wiznerowicz, M. Review the cancer genome atlas (tcga): an immeasurable source of knowledge. *Contemp. IczesnaOnkologia* 2015, 68–77 (2015).
- Jensen, M. A., Ferretti, V., Grossman, R. L. & Staudt, L. M. The nci genomic data commons as an engine for precision medicine. *Blood, The J. Am. Soc. Hematol.* 130, 453–459 (2017).
- **19.** Arjmand, B. *et al.* Machine learning: a new prospect in multi-omics data analysis of cancer. *Front. Genet.* **13**, 824451 (2022).
- **20.** Shen, J. *et al.* Artificial intelligence versus clinicians in disease diagnosis: systematic review. *JMIR medical informatics* **7**, e10010 (2019).
- Mirbabaie, M., Stieglitz, S. & Frick, N. R. Artificial intelligence in disease diagnostics: A critical review and classification on the current state of research guiding future direction. *Heal. Technol.* 11, 693–731 (2021).
- 22. Pellegrini, M. Accurate prognosis for localized prostate cancer through coherent voting networks with multi-omic and clinical data. *Sci. Reports* 13, 7875 (2023).
- Malik, V., Kalakoti, Y. & Sundar, D. Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer. *Bmc Genomics* 22, 1–11 (2021).
- 24. Fan, Z., Jiang, Z., Liang, H. & Han, C. Pancancer survival prediction using a deep learning architecture with

multimodal representation and integration. *Bioinforma*. *Adv.* **3**, vbad006 (2023).

- **25.** Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V. & Fotiadis, D. I. Machine learning applications in cancer prognosis and prediction. *Comput. structural biotechnology journal* **13**, 8–17 (2015).
- **26.** Baek, B. & Lee, H. Prediction of survival and recurrence in patients with pancreatic cancer by integrating multiomics data. *Sci. reports* **10**, 18951 (2020).
- 27. Jiang, Y., Alford, K., Ketchum, F., Tong, L. & Wang, M. D. Tlsurv: Integrating multi-omics data by multistage transfer learning for cancer survival prediction. In *Proceedings of the 11th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics,* 1–10 (2020).
- Benkirane, H., Pradat, Y., Michiels, S. & Cournède, P.-H. Customics: A versatile deep-learning based strategy for multi-omics integration. *PLoS Comput. Biol.* 19, e1010921 (2023).
- **29.** Qian, X. *et al.* Study on the prediction model of atherosclerotic cardiovascular disease in the rural xinjiang population based on survival analysis. *BMC Public Heal.* **23**, 1–11 (2023).
- **30.** Jung, J.-O. *et al.* Machine learning for optimized individual survival prediction in resectable upper gastrointestinal cancer. *J. Cancer Res. Clin. Oncol.* **149**, 1691–1702 (2023).
- **31.** Jiang, A. *et al.* Establishment of a prognostic prediction and drug selection model for patients with clear cell renal cell carcinoma by multiomics data analysis. *Oxidative Medicine Cell. Longev.* **2022** (2022).
- 32. Han, M., He, J. & Jiao, X. Research on prognostic risk assessment algorithm based on graph neural networks and attention mechanisms. In 2022 International Conference on Information Technology, Communication Ecosystem and Management (ITCEM), 101–106 (IEEE, 2022).
- **33.** Chai, H. *et al.* Integrating multi-omics data through deep learning for accurate cancer prognosis prediction. *Comput. biology medicine* **134**, 104481 (2021).
- 34. García-Laencina, P. J., Abreu, P. H., Abreu, M. H. & Afonoso, N. Missing data imputation on the 5-year survival prediction of breast cancer patients with unknown discrete values. *Comput. biology medicine* 59, 125–133 (2015).
- 35. Van Buuren, S., Boshuizen, H. C. & Knook, D. L. Multiple imputation of missing blood pressure covariates in survival analysis. *Stat. medicine* 18, 681–694 (1999).
- Ni, A. & Qin, L.-X. Performance evaluation of transcriptomics data normalization for survival risk prediction. *Briefings Bioinforma*. 22, bbab257 (2021).

- **37.** Feldner-Busztin, D. *et al.* Dealing with dimensionality: the application of machine learning to multi-omics data. *Bioinformatics* **39**, btad021 (2023).
- 38. Wang, C., Lue, W., Kaalia, R., Kumar, P. & Rajapakse, J. C. Network-based integration of multi-omics data for clinical outcome prediction in neuroblastoma. *Sci. Reports* 12, 15425 (2022).
- **39.** Lv, J., Wang, J., Shang, X., Liu, F. & Guo, S. Survival prediction in patients with colon adenocarcinoma via multiomics data integration using a deep learning algorithm. *Biosci. Reports* **40**, BSR20201482 (2020).
- 40. Tang, C., Yu, M., Ma, J. & Zhu, Y. Metabolic classification of bladder cancer based on multi-omics integrated analysis to predict patient prognosis and treatment response. *J. translational medicine* 19, 1–15 (2021).
- **41.** Wang, Z. *et al.* An integration framework for liver cancer subtype classification and survival prediction based on multi-omics data. In *Intelligent Computing Methodologies: 16th International Conference, ICIC 2020, Bari, Italy, October 2–5, 2020, Proceedings, Part III 16, 247–257 (Springer, 2020).*
- **42.** Li, Y., Sun, R., Zhang, Y., Yuan, Y. & Miao, Y. A methylation-based mrna signature predicts survival in patients with gastric cancer. *Cancer Cell Int.* **20**, 1–10 (2020).
- **43.** Owens, A. R., McInerney, C. E., Prise, K. M., McArt, D. G. & Jurek-Loughrey, A. Novel deep learning-based solution for identification of prognostic subgroups in liver cancer (hepatocellular carcinoma). *BMC bioinformatics* **22**, 1–22 (2021).
- **44.** Deepa, P. & Gunavathi, C. A systematic review on machine learning and deep learning techniques in cancer survival prediction. *Prog. Biophys. Mol. Biol.* (2022).
- 45. Herrmann, M., Probst, P., Hornung, R., Jurinovic, V. & Boulesteix, A.-L. Large-scale benchmark study of survival prediction methods using multi-omics data. *Briefings bioinformatics* 22, bbaa167 (2021).
- **46.** Rahimi, M., Akbari, A., Asadi, F. & Emami, H. Cervical cancer survival prediction by machine learning algorithms: a systematic. (2023).
- 47. Pobar, I., Job, M., Holt, T., Hargrave, C. & Hickey, B. Prognostic tools for survival prediction in advanced cancer patients: A systematic review. *J. Med. Imaging Radiat. Oncol.* 65, 806–816 (2021).
- **48.** Boshier, P. R. *et al.* Systematic review and validation of clinical models predicting survival after oesophagectomy for adenocarcinoma. *Br. J. Surg.* **109**, 418–425 (2022).
- **49.** Wiegrebe, S., Kopper, P., Sonabend, R. & Bender, A. Deep learning for survival analysis: A review. *arXiv preprint arXiv:2305.14961* (2023).

- **50.** Salerno, S. & Li, Y. High-dimensional survival analysis: Methods and applications. *Annu. review statistics its application* **10**, 25–49 (2023).
- Bakasa, W. & Viriri, S. Pancreatic cancer survival prediction: a survey of the state-of-the-art. *Comput. Math. Methods Medicine* 2021, 1–17 (2021).
- **52.** Ahmed, F. E. Artificial neural networks for diagnosis and survival prediction in colon cancer. *Mol. cancer* **4**, 1–12 (2005).
- **53.** Altuhaifa, F. A., Win, K. T. & Su, G. Predicting lung cancer survival based on clinical data using machine learning: A review. *Comput. Biol. Medicine* 107338 (2023).
- **54.** Wekesa, J. S. & Kimwele, M. A review of multiomics data integration through deep learning approaches for disease diagnosis, prognosis, and treatment. *Front. Genet.* **14** (2023).
- **55.** Kvamme, H. & Borgan, Ø. Continuous and discretetime survival prediction with neural networks. *Lifetime data analysis* **27**, 710–736 (2021).
- **56.** Kantidakis, G., Hazewinkel, A.-D., Fiocco, M. *et al.* Neural networks for survival prediction in medicine using prognostic factors: A review and critical appraisal. *Comput. Math. Methods Medicine* **2022** (2022).
- **57.** Gupta, V. *et al.* Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review. *The J. thoracic cardiovascular surgery* **156**, 847–856 (2018).
- **58.** Wissel, D. *et al.* Survboard: standardised benchmarking for multi-omics cancer survival models. *bioRxiv* 2022–11 (2022).
- Lee, S. & Lim, H. Review of statistical methods for survival analysis using genomic data. *Genomics & informatics* 17 (2019).
- **60.** Guan, F. *et al.* Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction. *Mol. Psychiatry* **27**, 113–126 (2022).
- **61.** Mo, L. *et al.* Comparisons of forecasting for survival outcome for head and neck squamous cell carcinoma by using machine learning models based on multi-omics. *Curr. Genomics* **23**, 94 (2022).
- 62. Bashiri, A., Ghazisaeedi, M., Safdari, R., Shahmoradi, L. & Ehtesham, H. Improving the prediction of survival in cancer patients by using machine learning techniques: experience of gene expression data: a narrative review. *Iran. journal public health* 46, 165 (2017).
- **63.** Tewarie, I. A. *et al.* Survival prediction of glioblastoma patients—are we there yet? a systematic review of prognostic modeling for glioblastoma and its clinical potential. *Neurosurg. review* **44**, 2047–2057 (2021).

- **64.** Westerlund, A. M., Hawe, J. S., Heinig, M. & Schunkert, H. Risk prediction of cardiovascular events by exploration of molecular data with explainable artificial intelligence. *Int. J. Mol. Sci.* **22**, 10291 (2021).
- **65.** Kresoja, K.-P., Unterhuber, M., Wachter, R., Thiele, H. & Lurz, P. A cardiologist's guide to machine learning in cardiovascular disease prognosis prediction. *Basic research cardiology* **118**, 10 (2023).
- **66.** Miao, S. *et al.* Development and validation of a risk prediction model for overall survival in patients with nasopharyngeal carcinoma: a prospective cohort study in china. *Cancer Cell Int.* **22**, 1–11 (2022).
- **67.** Wang, J. *et al.* Multi-omics fusion analysis models with machine learning predict survival of her2-negative metastatic breast cancer: a multicenter prospective observational study. *Chin. Med. J.* **136**, 863–865 (2023).
- **68.** Zhang, J., Zhang, M., Tian, Q. & Yang, J. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer. *Clin. Exp. Medicine* 1–15 (2023).
- **69.** Yang, Q. *et al.* Integrating genomic data with transcriptomic data for improved survival prediction for adult diffuse glioma. *J. Cancer* **11**, 3794 (2020).
- **70.** Lin, Z. *et al.* A multi-omics signature to predict the prognosis of invasive ductal carcinoma of the breast. *Comput. Biol. Medicine* **151**, 106291 (2022).
- Zhou, H.-F. *et al.* Survival prediction for patients with malignant biliary obstruction caused by pancreatic cancer undergoing biliary drainage: the combo-pas model. *Surg. Endosc.* 37, 1943–1955 (2023).
- 72. Zhao, L. *et al.* Deepomix: A scalable and interpretable multi-omics deep learning framework and application in cancer survival analysis. *Comput. structural biotechnology journal* 19, 2719–2725 (2021).
- 73. Hu, Q. *et al.* A new hpv score system predicts the survival of patients with cervical cancers. *Front. Genet.* 12, 747090 (2021).
- 74. Zhang, J. Z., Xu, W. & Hu, P. Tightly integrated multiomics-based deep tensor survival model for timeto-event prediction. *Bioinformatics* 38, 3259–3266 (2022).
- **75.** Lee, C.-J. *et al.* Machine learning with in silico analysis markedly improves survival prediction modeling in colon cancer patients. *Cancer Medicine* **12**, 7603–7615 (2023).
- 76. Yang, H. *et al.* A novel prognostic model based on multiomics features predicts the prognosis of colon cancer patients. *Mol. Genet. & Genomic Medicine* 8, e1255 (2020).
- 77. Tong, D. *et al.* Improving prediction performance of colon cancer prognosis based on the integration of clini-

cal and multi-omics data. *BMC Med. Informatics Decis. Mak.* **20**, 1–15 (2020).

- 78. Bichindaritz, I. & Liu, G. Adaptive multi-omics survival analysis in cancer. In *Innovation in Medicine and Healthcare: Proceedings of 10th KES-InMed 2022*, 51–62 (Springer, 2022).
- **79.** Yu, J., Wu, X., Lv, M. *et al.* A model for predicting prognosis in patients with esophageal squamous cell carcinoma based on joint representation learning. oncol lett 20 (6): 1–10 (2020).
- **80.** Wu, W. *et al.* A novel multi-omics analysis model for diagnosis and survival prediction of lower-grade glioma patients. *Front. Oncol.* **12**, 729002 (2022).
- **81.** Chauhan, P. S. *et al.* Urine cell-free dna multi-omics to detect mrd and predict survival in bladder cancer patients. *npj Precis. Oncol.* **7**, 6 (2023).
- 82. Chai, H., Zhang, Z., Wang, Y. & Yang, Y. Predicting bladder cancer prognosis by integrating multi-omics data through a transfer learning-based cox proportional hazards network. *CCF Transactions on High Perform. Comput.* 3, 311–319 (2021).
- 83. Shetty, K. S., Jose, A., Bani, M. & Vinod, P. Network diffusion-based approach for survival prediction and identification of biomarkers using multi-omics data of papillary renal cell carcinoma. *Mol. Genet. Genomics* 1–12 (2023).
- 84. Tong, L., Wu, H. & Wang, M. D. Integrating multiomics data by learning modality invariant representations for improved prediction of overall survival of cancer. *Methods* 189, 74–85 (2021).
- **85.** Li, X. *et al.* Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in china. *BMC Med. Informatics Decis. Mak.* **23**, 1–11 (2023).
- **86.** Wang, X. *et al.* Machine learning integrations develop an antigen-presenting-cells and t-cells-infiltration derived lncrna signature for improving clinical outcomes in hepatocellular carcinoma. *BMC cancer* **23**, 1–16 (2023).
- **87.** Zhang, R. *et al.* Using integrated multi-omics data analysis to identify 5-gene signature for predicting survival of patients with hepatocellular carcinoma. (2022).
- 88. Pawar, A., Chowdhury, O. R., Chauhan, R., Talole, S. & Bhattacharjee, A. Identification of key gene signatures for the overall survival of ovarian cancer. *J. Ovarian Res.* 15, 1–13 (2022).
- 89. Hira, M. T. *et al.* Integrated multi-omics analysis of ovarian cancer using variational autoencoders. *Sci. reports* 11, 6265 (2021).
- **90.** Wu, X. & Fang, Q. Stacked autoencoder based multiomics data integration for cancer survival prediction. *arXiv preprint arXiv:2207.04878* (2022).

- **91.** Redekar, S. S., Varma, S. L. & Bhattacharjee, A. Identification of key genes associated with survival of glioblastoma multiforme using integrated analysis of tcga datasets. *Comput. Methods Programs Biomed. Updat.* **2**, 100051 (2022).
- **92.** Kazerooni, A. F. *et al.* Multi-omic prediction of overall survival in patients with glioblastoma: Additive and synergistic value of clinical measures, radiomics, and genomics. (2021).
- 93. Du, J. *et al.* Identification of prognostic model and biomarkers for cancer stem cell characteristics in glioblastoma by network analysis of multi-omics data and stemness indices. *Front. cell developmental biology* 8, 558961 (2020).
- **94.** Li, R. *et al.* Extended application of genomic selection to screen multiomics data for prognostic signatures of prostate cancer. *Briefings Bioinforma.* **22**, bbaa197 (2021).
- **95.** Manganaro, L. *et al.* Non-small cell lung cancer survival estimation through multi-omic two-layer svm: A multi-omics and multi-sources integrative model. *Curr. Bioinforma.* **18**, 658–669 (2023).
- 96. Ellen, J. G., Jacob, E., Nikolaou, N. & Markuzon, N. Autoencoder-based multimodal prediction of non-small cell lung cancer survival. *Sci. Reports* 13, 15761 (2023).
- 97. Zhang, Z.-S., Xu, F., Jiang, H.-J. & Chen, Z.-H. Prognostic prediction for non-small-cell lung cancer based on deep neural network and multimodal data. In *Intelligent Computing Theories and Application: 17th International Conference, ICIC 2021, Shenzhen, China, August 12–15, 2021, Proceedings, Part III 17*, 549–560 (Springer, 2021).
- **98.** Othman, N. A., Abdel-Fattah, M. A. & Ali, A. T. A hybrid deep learning framework with decision-level fusion for breast cancer survival prediction. *Big Data Cogn. Comput.* **7**, 50 (2023).
- **99.** Zhou, L., Rueda, M. & Alkhateeb, A. Identifying biomarkers of nottingham prognosis index in breast cancer survivability. In *Proceedings of the 12th ACM Conference on Bioinformatics, Computational Biology, and Health Informatics,* 1–9 (2021).
- 100. Tong, L., Mitchel, J., Chatlin, K. & Wang, M. D. Deep learning based feature-level integration of multi-omics data for breast cancer patients survival analysis. *BMC medical informatics decision making* 20, 1–12 (2020).
- 101. Bhat, A. R. & Hashmy, R. Hierarchical autoencoderbased multi-omics subtyping and prognosis prediction framework for lung adenocarcinoma. *Int. J. Inf. Technol.* 1–9 (2023).
- **102.** Lee, T.-Y., Huang, K.-Y., Chuang, C.-H., Lee, C.-Y. & Chang, T.-H. Incorporating deep learning and multiomics autoencoding for analysis of lung adenocarci-

noma prognostication. *Comput. Biol. Chem.* **87**, 107277 (2020).

- 103. Zhang, S., Zeng, X., Lin, S., Liang, M. & Huang, H. Identification of seven-gene marker to predict the survival of patients with lung adenocarcinoma using integrated multi-omics data analysis. *J. Clin. Lab. Analysis* 36, e24190 (2022).
- 104. Majji, R., Rajeswari, R., Vidyadhari, C. & Cristin, R. Squirrel search deer hunting-based deep recurrent neural network for survival prediction using pan-cancer gene expression data. *The Comput. J.* 66, 245–266 (2023).
- 105. Yin, Q., Chen, W., Zhang, C. & Wei, Z. A convolutional neural network model for survival prediction based on prognosis-related cascaded wx feature selection. *Lab. Investig.* 102, 1064–1074 (2022).
- **106.** Zhang, X., Xing, Y., Sun, K. & Guo, Y. Omiembed: a unified multi-task deep learning framework for multi-omics data. *Cancers* **13**, 3047 (2021).
- **107.** Zheng, X., Amos, C. I. & Frost, H. R. Pan-cancer evaluation of gene expression and somatic alteration data for cancer prognosis prediction. *BMC cancer* **21**, 1–11 (2021).
- 108. Tan, K., Huang, W., Hu, J. & Dong, S. A multi-omics supervised autoencoder for pan-cancer clinical outcome endpoints prediction. *BMC Med. Informatics Decis. Mak.* 20, 1–9 (2020).
- **109.** Willems, A., Panchy, N. & Hong, T. Using single-cell rna sequencing and microrna targeting data to improve colorectal cancer survival prediction. *Cells* **12**, 228 (2023).
- Hathaway, Q., Yanamala, N., Budoff, M., Sengupta, P. & Zeby, I. Cardiovascular risk stratification through deep neural survival networks-the multi-ethnic study of atherosclerosis (mesa). *J. Am. Coll. Cardiol.* 77, 561–561 (2021).
- 111. Hathaway, Q. A., Yanamala, N., Budoff, M. J., Sengupta, P. P. & Zeb, I. Deep neural survival networks for cardiovascular risk prediction: The multi-ethnic study of atherosclerosis (mesa). *Comput. Biol. Medicine* **139**, 104983 (2021).
- **112.** Feng, Y. *et al.* Personalized prediction of incident hospitalization for cardiovascular disease in patients with hypertension using machine learning. *BMC Med. Res. Methodol.* **22**, 1–11 (2022).
- **113.** Richard, V. R. *et al.* Early prediction of covid-19 patient survival by targeted plasma multi-omics and machine learning. *Mol. & Cell. Proteomics* **21** (2022).
- **114.** Zeng, W., Wang, X., Xu, K., Zhang, Y. & Fu, H. Prediction of cardiovascular disease survival based on artificial neural network. In 2021 IEEE International Conference

on Computer Science, Electronic Information Engineering and Intelligent Control Technology (CEI), 219–224 (IEEE, 2021).

- **115.** Unterhuber, M. *et al.* Proteomics-enabled deep learning machine algorithms can enhance prediction of mortality. *J. Am. Coll. Cardiol.* **78**, 1621–1631 (2021).
- **116.** Xu, Z. *et al.* Prediction of cardiovascular disease risk accounting for future initiation of statin treatment. *Am. journal epidemiology* **190**, 2000–2014 (2021).
- **117.** Vahabi, N. *et al.* Cox-smbpls: An algorithm for disease survival prediction and multi-omics module discovery incorporating cis-regulatory quantitative effects. *Front. Genet.* **12**, 701405 (2021).
- **118.** Moreno-Sanchez, P. A. Improvement of a prediction model for heart failure survival through explainable artificial intelligence. *Front. Cardiovasc. Medicine* **10** (2023).
- **119.** Kantidakis, G. *et al.* Survival prediction models since liver transplantation-comparisons between cox models and machine learning techniques. *BMC Med. Res. Methodol.* **20**, 1–14 (2020).
- 120. Abdelhamid, S. *et al.* Multi-omic admission-based biomarkers predict 30-day survival and persistent critical illness in trauma patients after injury. *J. Am. Coll. Surg.* 235, S95 (2022).
- **121.** Grever, M. R., Schepartz, S. A. & Chabner, B. A. The national cancer institute: cancer drug discovery and development program. In *Seminars in oncology*, vol. 19, 622–638 (1992).
- 122. Lee, E. T. & Wang, J. Statistical methods for survival data analysis, vol. 476 (John Wiley & Sons, 2003).
- **123.** Voet, D. *et al.* Firehose: An analysis infrastructure. *Firehose Broad GDAC, Broad Inst.* 1.
- **124.** Zhao, Z. *et al.* Chinese glioma genome atlas (cgga): a comprehensive resource with functional genomic data from chinese glioma patients. *Genomics, proteomics & bioinformatics* **19**, 1–12 (2021).
- **125.** Zhang, W. *et al.* Comparison of rna-seq and microarraybased models for clinical endpoint prediction. *Genome biology* **16**, 1–12 (2015).
- **126.** Liberzon, A. *et al.* Molecular signatures database (msigdb) 3.0. *Bioinformatics* **27**, 1739–1740 (2011).
- **127.** Stanfill, A. G. & Cao, X. Enhancing research through the use of the genotype-tissue expression (gtex) database. *Biol. research for nursing* **23**, 533–540 (2021).
- **128.** Bild, D. E. *et al.* Multi-ethnic study of atherosclerosis: objectives and design. *Am. journal epidemiology* **156**, 871–881 (2002).
- **129.** Goldman, M. *et al.* The ucsc xena platform for public and private cancer genomics data visualization and interpretation. *biorxiv* 326470 (2018).

- **130.** Clough, E. & Barrett, T. The gene expression omnibus database. *Stat. Genomics: Methods Protoc.* 93–110 (2016).
- **131.** Poirion, O. B., Jing, Z., Chaudhary, K., Huang, S. & Garmire, L. X. Deepprog: an ensemble of deep-learning and machine-learning models for prognosis prediction using multi-omics data. *Genome medicine* **13**, 1–15 (2021).
- **132.** Amgalan, B. & Lee, H. Deod: uncovering dominant effects of cancer-driver genes based on a partial covariance selection method. *Bioinformatics* **31**, 2452–2460 (2015).
- **133.** Pölsterl, S. scikit-survival: A library for time-to-event analysis built on top of scikit-learn. *The J. Mach. Learn. Res.* **21**, 8747–8752 (2020).
- **134.** Davidson-Pilon, C. lifelines: survival analysis in python. *J. Open Source Softw.* **4**, 1317 (2019).
- **135.** Therneau, T. M. & Lumley, T. Package 'survival'. *R Top Doc* **128**, 28–33 (2015).
- **136.** McKinney, W., Perktold, J. & Seabold, S. Time series analysis in python with statsmodels. *Jarrodmillman Com* 96–102 (2011).
- 137. Kvamme, H., Borgan, Ø. & Scheel, I. Time-to-event prediction with neural networks and cox regression. arXiv preprint arXiv:1907.00825 (2019).
- **138.** Fotso, S. *et al.* PySurvival: Open source package for survival analysis modeling (2019–).
- **139.** Jackson, C. H. flexsurv: a platform for parametric survival modeling in r. *J. statistical software* **70** (2016).
- 140. Sonabend, R., Király, F. J., Bender, A., Bischl, B. & Lang, M. mlr3proba: an r package for machine learning in survival analysis. *Bioinformatics* **37**, 2789–2791 (2021).
- 141. Clements, M. Introduction to the rstpm2 package. *Karolinska Institutet* (2019).
- 142. Spytek, M. *et al.* survex: an r package for explaining machine learning survival models. *arXiv preprint arXiv:2308.16113* (2023).
- **143.** Kubi, M. G., Lasisi, K. & Rasheed, B. A. Parametric and semi-parametric survival models with application to diabetes data. *Sci J Biomed Eng Biomed Sci* **3**, 001–010 (2022).
- **144.** Ishak, K. J., Kreif, N., Benedict, A. & Muszbek, N. Overview of parametric survival analysis for health-economic applications. *Pharmacoeconomics* **31**, 663–675 (2013).
- 145. Sinha, D. & Dey, D. K. Semiparametric bayesian analysis of survival data. *J. Am. Stat. Assoc.* 92, 1195–1212 (1997).
- 146. Stevenson, M. & EpiCentre, I. An introduction to survival analysis. *EpiCentre*, *IVABS*, *Massey Univ*. (2009).

- 147. Therneau, T. M., Grambsch, P. M., Therneau, T. M. & Grambsch, P. M. *The cox model* (Springer, 2000).
- 148. Ishwaran, H., Kogalur, U. B., Blackstone, E. H. & Lauer, M. S. Random survival forests. (2008).
- 149. Binder, H. & Schumacher, M. Allowing for mandatory covariates in boosting estimation of sparse highdimensional survival models. *BMC bioinformatics* 9, 1–10 (2008).
- **150.** Van Belle, V., Pelckmans, K., Suykens, J. A. & Van Huffel, S. Support vector machines for survival analysis. In *Proceedings of the third international conference on computational intelligence in medicine and healthcare (cimed2007)*, 1–8 (2007).
- **151.** Shivaswamy, P. K., Chu, W. & Jansche, M. A support vector approach to censored targets. In *Seventh IEEE international conference on data mining (ICDM 2007)*, 655–660 (IEEE, 2007).
- **152.** Khan, F. M. & Zubek, V. B. Support vector regression for censored data (svrc): a novel tool for survival analysis. In 2008 Eighth IEEE International Conference on Data Mining, 863–868 (IEEE, 2008).
- 153. Fornili, M., Ambrogi, F., Boracchi, P. & Biganzoli, E. Piecewise exponential artificial neural networks (peann) for modeling hazard function with right censored data. In Computational Intelligence Methods for Bioinformatics and Biostatistics: 10th International Meeting, CIBB 2013, Nice, France, June 20-22, 2013, Revised Selected Papers 10, 125–136 (Springer, 2014).
- **154.** Katzman, J. L. *et al.* Deepsurv: personalized treatment recommender system using a cox proportional hazards deep neural network. *BMC medical research methodology* **18**, 1–12 (2018).
- 155. Gensheimer, M. F. & Narasimhan, B. A scalable discrete-time survival model for neural networks. *PeerJ* 7, e6257 (2019).
- **156.** Kvamme, H. & Borgan, Ø. Continuous and discretetime survival prediction with neural networks. *arXiv preprint arXiv:1910.06724* (2019).

- **157.** Lee, C., Zame, W., Yoon, J. & Van Der Schaar, M. Deephit: A deep learning approach to survival analysis with competing risks. In *Proceedings of the AAAI conference on artificial intelligence*, vol. 32 (2018).
- **158.** Yu, C.-N., Greiner, R., Lin, H.-C. & Baracos, V. Learning patient-specific cancer survival distributions as a sequence of dependent regressors. *Adv. neural information processing systems* **24** (2011).
- **159.** Fotso, S. Deep neural networks for survival analysis based on a multi-task framework. *arXiv preprint arXiv:1801.05512* (2018).
- **160.** Kvamme, H. & Borgan, Ø. The brier score under administrative censoring: Problems and solutions. *arXiv* preprint arXiv:1912.08581 (2019).
- **161.** Moher, D. *et al.* Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. *Int. journal surgery* **8**, 336–341 (2010).

## **Additional information**

Supplementary tables can be found in additional files. Table S1 entails information about survival prediction studies. In addition, Table S2 presents distribution of data modalities across survival prediction studies. Table S3 shows distribution of survival endpoints across different studies. Table S4 provides a short summary of each study included in this review paper. Table S5, S6, and S7, present information about evaluation measures, journal and publisher wise distribution of survival prediction literature.

### Author contributions statement

A.A. and M.N.A. conducted the literature review, V.S., D.A., and A.S. analyzed the results. All authors reviewed the manuscript.

### **Competing interests**

The authors declare no competing interests.